Characterizing microRNA regulators of lung disease by Garrison, Carly
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2016
Characterizing microRNA regulators
of lung disease
https://hdl.handle.net/2144/14598
Boston University
 BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Dissertation 
 
 
 
 
 
CHARACTERIZING MICRORNA  
 
REGULATORS OF LUNG DISEASE 
 
 
 
 
by 
 
 
 
 
CARLY BETH GARRISON 
 
B.A., Boston University, 2009 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Doctor of Philosophy 
 
2016  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 © 2016 by 
  CARLY BETH GARRISON 
  All rights reserved 
 Approved by 
 
 
 
 
 
First Reader _________________________________________________________ 
 Avrum Spira, M.D., M.Sc. 
 Professor of Medicine 
 
 
Second Reader _________________________________________________________ 
 Laertis Ikonomou, Ph.D. 
 Assistant Professor of Medicine 
 
 
 
 
 iv 
 
 
 
 
 
 
 
In the place I go there are things that I see 
That I never could spell if I stopped with the Z. 
I’m telling you this ‘cause you’re one of my friends. 
My alphabet starts where your alphabet ends!... 
So, on beyond Z! 
It’s high time you were shown 
That you really don’t know 
All there is to be known. 
-Dr. Seuss, On Beyond Zebra! (1955) 
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ABSTRACT 
Lung diseases are one of the leading causes of mortality and morbidity 
worldwide. Understanding these diseases at a molecular level remains a critical 
component to developing effective therapeutics. Previous work has shown that gene 
expression alterations play an important role in disease initiation, maintenance, and 
progression as well as serve as diagnostic tools in disease. However, much remains to be 
uncovered regarding the role that microRNAs play in both healthy and diseased lung 
tissue. This thesis seeks to utilize methods of bioinformatics, cell biology, and molecular 
biology to examine the effect of miR-4423 on lung epithelial cell differentiation (Aim 1), 
miR-424 on never smoker derived lung adenocarcinoma (Aim 2), and miR-34c isomiRs 
in interstitial lung disease (ILD) (Aim 3). 
First, we examined the role of miR-4423 in lung mucociliary epithelium by 
employing the use of an air-liquid interface culture system, finding miR-4423 has an 
effect in ciliated cell differentiation and that a loss of miR-4423 is associated with cancer 
progression. These findings suggest that miR-4423’s actions in airway epithelium 
differentiation may potentially provide a therapeutic role in lung cancer. Next, we 
validated transcriptomic differences between lung tumor tissues resected from never and 
 ix 
ever smokers. Specifically, miR-424, a predicted regulator of a large number of gene 
expression changes in never smoker lung adenocarcinoma, was found to regulate cell 
migration, potentially identifying a novel target and/or pathway for therapeutic action. 
Lastly, the function of microRNA isomiRs is relatively unknown. We validated miR-34c 
as upregulated in ILD and modulated both miR-34c and a miR-34c 5’ isomiR in lung 
relevant cell lines to explore their differing biological roles. We found that they are 
capable of targeting differing mRNA, indicating an independent role for isomiRs in 
disease.  
 The studies contained in this dissertation offer valuable insight into the biology of 
microRNAs in the lung and how they might be employed as therapeutic targets for a 
number of common lung diseases. In addition, biological insights into the complexity of 
microRNAs in the lung highlight the need to better understand diseases influenced by 
microRNA expression and microRNA variants in regards to actionable therapeutics. 
 x 
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CHAPTER ONE 
Introduction 
1.1 Airway Epithelium Differentiation 
The airway epithelium is comprised of multiple cell types including basal, ciliated, 
goblet, secretory and neuroendocrine 
1
. The varied cell types work together to protect the 
lower respiratory tract from inhaled toxins. Cells in the airway epithelium replenished by 
basal cell differentiation into the other cell types 
2,3
. Cellular turnover is critical to ensure 
that damaged cells are removed and replaced, 
4
 a process important for preventing disease 
and ensuring the protective capabilities of the airway 
5,6
. Disruption to the airway 
epithelial homeostasis leads to inflammation 
7–11
. Chronic inflammation, caused from a 
wide variety of biological processes, can predispose an individual to lung disease such as 
cancer and interstitial lung disease
12–18
. An understanding of the mechanism of normal 
airway epithelial differentiation is a critical step in understanding events that disrupt this 
system, leading to lung disease. 
The airway epithelium is constantly exposed to inhaled toxins including, 
carcinogens in tobacco smoke. Our laboratory and others have identified a “field of 
injury” throughout the respiratory tract and lung that is induced by cigarette smoke and/or 
lung disease and measurable by gene and microRNA expression profiling 
19–21
. The “field 
of injury” is based on the concept that the entire airway is exposed to inhaled toxins, and 
while diseased tissue is in a distal part of the lung, the histologically normal airway cells 
react to an assault and can be used to measure distal disease-specific changes
22
. We have 
previously shown that tobacco smoke alters the gene expression of airway epithelial cells 
  2 
and that bronchial airway gene expression can serve as a minimally invasive biomarker 
for the detection of lung cancer 
23–28
. Based on this body of evidence, the airway is not 
only important in protecting the lower respiratory tract but can also serve as an important 
diagnostic area for many smoking related lung diseases. 
1.2 Lung Cancer 
 Lung cancer is the leading cause of cancer-related mortality globally with a 5-year 
survival rate around 15%
29
. Despite copious research in diagnostics and treatments
30,31
, 
most patients are diagnosed at late stages, leading to poor prognosis
32
. Lung cancer is a 
heterogeneous disease with two main subtypes: small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC). While SCLC only comprises 15% of all lung cancer 
cases, it is a more aggressive form of lung cancer that originates in the upper airways, the 
bronchi, and grows quickly to metastasize to other parts of the body
33
. Most lung cancer 
cases are NSCLC (~85%) and can be broken down into further classification of 
adenocarcinoma (~50%), squamous cell carcinoma (SCC, ~30%) and large cell 
carcinoma (LCC, ~5%)
34
. SCC generally originates in the proximal airways and 
adenocarcinoma in the distal airways
35
. The wide range of locations of the subtypes of 
lung cancer within the lung lead credence to the concept that they arise from distinct cell 
types in the lung
36
. 
One of the most common causes of lung cancer is smoking tobacco cigarettes, a 
habit that is slowly on the decline in the United States
31,34,37
. Unfortunately, incidence of 
lung cancer in never smokers is on the rise with no strong implication for any specific 
environmental or genetic cause
38,39
. Studies show that there are clinical, genomic, and 
  3 
genetic differences in lung cancer cases presented in a never smoker compared to an ever 
smoker. Specifically, lung cancer in never smokers is predominantly adenocarcinoma 
compared to the percentages of other cancer types listed above that are found in ever 
smokers
38
. Hypothesized risk factors for never smoker lung cancer are varied, from 
environmental (for example diet, indoor air pollution, and cooking fumes) to genetic, 
compared to the prevalent risk factor of smoking in ever smokers
40
. Mutational spectra 
also vary depending on smoking status, with EGFR mutations more common in never 
smoker tumors and KRAS mutations in ever smoker tumors
40–42
. One of the more 
interesting, and as of yet unexplained features of never smoker lung cancer is that women 
are diagnosed with this variation of lung cancer at a 2:1 ratio to men
43
. There is a growing 
need to better understand the molecular biology of the numerous categories of lung 
cancer and leverage this knowledge to develop precision diagnostic and therapeutic 
options. 
1.3 Interstitial Lung Disease 
 Interstitial lung disease (ILD) is the term used for a heterogeneous group of 
chronic respiratory disorders that are commonly associated with high morbidity and 
mortality with the most common ILD being idiopathic pulmonary fibrosis (IPF)
44,45
. The 
common feature of these diseases is a progressive remodeling of the alveolo-capillary 
barrier, essentially scarring of lung tissue. This scarring may cause progressive lung 
stiffness
45
. Clinically, these diseases present with shortness of breath and diffuse lung 
infiltration on CT scan
44
. 
  4 
 The working concept of ILD pathogenesis shows repeated injury to alveolar 
epithelial cells and failure of the alveoli to correctly respond to the injury, leading to 
aberrant lung repair and progressive fibrosis. Our understanding of ILD is that there are 
both genetic and non-genetic factors contributing to alveolar incorrect repair
46,47
. As there 
are a number of diseases under the umbrella term of ILD, there are a number of potential 
causes and treatments. Most cases of ILD are diagnosed late in the disease progression 
and the majority of treatment options only slow progression of the disease because they 
treat the symptoms, not the underlying disease biology
44
.  
 Many ILDs, such as IPF, have no effective therapies and gradually progress with 
worsening symptoms
48–50
. A better understanding of the molecular underpinnings of 
ILDs is necessary so that treatment options targeting the causal disease mechanism of 
fibrosis can be discovered. 
1.4 MicroRNAs 
 In 1993 the first microRNA, lin-4, was discovered in C. elegans, but it was not 
until 2001 that the name microRNA was first used, after they were found to have 
regulatory roles
51,52
. MicroRNAs are between 20 and 25 nucleotides long and are 
endogenously expressed to regulate gene expression by binding to the 3’ UTR of a target 
gene. They can induce mRNA degradation or translational inhibition and have been 
found to be involved in nearly all biological processes
53
.  
MicroRNAs start in the nucleus with a single transcript that can be up to 1000 
nucleotides long, called a primary microRNA (pri-miRNA). The pri-miRNA is then 
processed by the RNAse III enzyme Drosha and the RNA binding protein DGCR8, 
  5 
resulting in a pre-miRNA, a transcript 70-100 nucleotides long and in a hairpin 
structure
54
. The RanGTP-dependent dsRNA-binding protein Exportin-5 then transports 
the pre-miRNA to the cytoplasm where the enzyme Dicer processes it into two 
microRNAs, a 5p and 3p form
55
. One of these forms is commonly degraded leaving one 
microRNA transcript. In some cases both transcripts are active
56
. An Argonaute protein 
then sequesters the active microRNA into a microRNA-induced silencing complex 
(miRISC). The microRNA is then sent to its target mRNA to bind to the 3’ UTR for 
translational degradation or repression
57
. Each microRNA has a 2-8 nucleotide “seed 
region” that is believed to be important for target recognition of a microRNA 
recognition/response element (MRE) in the 3’ UTR of an mRNA. Some target genes may 
have more than one MRE, allowing regulation by more than one microRNA
58
.  
1.5 MicroRNAs in the Lung 
Research over the past few years has shown microRNAs to play important roles 
in lung development and homeostasis. These studies began in mice and have slowly 
progressed to human airway tissue
59
. MicroRNAs play a conclusive role in many 
biological processes including apoptosis, proliferation and differentiation
12,53,60–65
. 
Disrupting normal microRNA function can lead to many lung diseases such as lung 
cancer 
66,67
.  
The impact of microRNAs in lung cancer disease biology is studied more 
extensively than in other lung diseases, with interest in microRNAs potential usefulness 
for sub-classification of the different cancer types and as eventual therapeutic tools
68
. 
Many microRNAs such as miR-99b, miR-7515, miR-126, miR-21, miR-200c, miR-145, 
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miR-107, miR-185, miR-101, miR-138 and miR-7 are found to be aberrantly expressed 
in lung cancer 
69–72
. Studies of these microRNAs show them to be regulators of genes 
involved in pathways known to be connected to cancer such as miR-7 regulating PIK3R3 
in the PI3K/AKT pathway 
72
. Other lung diseases such as IPF are shown to have 
microRNA regulators such as let-7, miR-21, miR-155, and miR-29
73
. Fibrosis is 
modulated with the inhibition of miR-21 in a bleomycin model of lung fibrosis while 
perturbations of miR-29 and miR-155 are shown to have profibrotic effects
73
. While 
many microRNA have been studied in detail there are still numerous questions regarding 
the biology of the lung and aspects of lung disease biology that need to be explored with 
future microRNA studies. 
1.6 MicroRNA Therapeutics 
 With the discovery of microRNAs came the flood of information regarding their 
role in gene regulation and therapeutic potential
74,75
. More than 60% of the human 
protein-coding genes have at least one conserved MRE along with a number of non-
conserved binding sites, allowing for the control of the majority of protein-coding genes 
by microRNAs
76
. Although the potential of microRNA therapeutics is appealing, there 
are some important challenges to overcome before they can be efficient in a clinical 
setting. MicroRNAs are hydrophobic in nature and are predominantly negatively charged, 
making it difficult to deliver them across biological membranes
77
. MicroRNA inhibitors 
may not be able to distinguish between microRNAs within the same family, causing off-
target effects
78
. Chemical modifications to make both inhibitors and mimics more stable 
also appear to induce toxicity
79
. Currently, microRNAs and microRNA inhibitors are 
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delivered with viral and non-viral vectors, with lower toxicity and better results seeming 
to come from non-viral vectors such as lipid-based delivery systems
80,81
. 
Despite the challenges associated with microRNA therapeutics, they are a 
growing field of research for a number of companies worldwide and are responsible for 
the creation of many therapeutic companies including: Mello Biotech, Regulus 
Therapeutics, miRagen Therapeutics, InteRNA Technologies, Mirna Therapeutics, and 
Groove Biopharma
82–87
. These companies are researching microRNA therapies, both 
microRNA antagonists and microRNA mimics, for a number of diseases and health 
products. There have been microRNA clinical trials in the US. Examples include 
MRX34, a microRNA mimic, from Mirna Therapeutics, Inc. and Miravirsen, a 
microRNA antagonist, from Santaris Pharma
88,89
. MRX34 is a double stranded mimic of 
the tumor suppressor miR-34 that is packaged in a liposomal nanoparticle formulation
90
. 
Phase I clinical trials for MRX34 are recruiting patients for a myriad of cancers 
including: primary liver cancer, small cell lung cancer, lymphoma, melanoma, acute 
lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, and 
myelodysplastic syndromes
91
. Miravirsen is an example of a microRNA inhibitor, in the 
form of an antisense oligonucleotide, currently in Phase II trials that inhibits miR-122 in 
the liver of hepatitis C virus patients
92
. With microRNAs being important and specific 
regulators of the cell, their use in disease therapy is highly appealing as long as they can 
be delivered to the cells of interest in a minimally toxic manner. 
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1.7 Dissertation Aims 
The following aims seek to broaden our understanding of microRNAs and their 
dysregulation with lung disease by leveraging cell biology and molecular biology 
techniques to characterize microRNAs identified in RNA sequencing data as being 
differentially expressed in lung disease. These microRNAs include miR-4423, a 
previously unreported microRNA detected in the airway epithelium that appears to lose 
expression with the progression of cancer, miR-424, a microRNA that is differentially 
upregulated specifically in never smoker lung adenocarcinoma tissue, and miR-34c, 
which is upregulated in ILD and has a 5’ isomiR that has the capacity to target Ras 
signaling genes. Together, these studies highlight the complexity of microRNA biology 
in the lung, provide insight into the specificity of microRNA regulation of gene 
expression, as well as identify potential therapeutic options for lung cancer and ILD.  
1.7.1 Aim 1: MicroRNA 4423 is Involved in Lung Epithelial Differentiation and its 
Expression is Lost with Lung Cancer Progression 
 Proliferation and differentiation of lung epithelial progenitor cells are tightly 
controlled processes important for lung repair after injury
93
. These processes are 
regulated by many factors, including the highly conserved miR-34/449 family of 
microRNAs, which has previously been shown to play a role in ciliogenesis in 
multiciliated cells and to function as a tumor suppressor
94,95
. The goal of this study is to 
see if miR-4423, a primate-specific microRNA highly expressed in the airway epithelium 
and an inhibitor of anchorage-independent growth
96
, also plays a regulatory role during 
airway epithelial differentiation. We utilized an air-liquid interface (ALI) to characterize 
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the mucociliary differentiation of bronchial epithelial cells. We show that overexpression 
of miR-4423 during differentiation of bronchial epithelial cells at an ALI results in an 
increase in the number of FoxJ1 and IV-tubulin expressing cells, suggesting that this 
microRNA plays a role in promoting ciliogenesis in the airway. In addition, we show that 
miR-4423 expression decreases with increasing cancer progression. This data suggests 
that miR-4423 may serve alongside highly conserved microRNAs to confer robustness to 
the process of ciliogenesis in the airway of primates as well as serve as a tumor 
suppressor lost with lung cancer progression. Further studies are needed to evaluate the 
potential of miR-4423 as a therapeutic in lung carcinogenesis. 
1.7.2 Aim 2: MicroRNA 424 is a Potential OncomiR in Never Smoker Lung 
Adenocarcinoma that Regulates Cell Migration  
 Although lung cancer is strongly associated with tobacco smoking, approximately 
25% of all lung cancer patients worldwide are never smokers
97
. Previous work 
performing differential analysis of matched pairs of adenocarcinoma tumor and adjacent-
normal tissue yielded 59 protein-coding RNAs (mRNA), 61 large non-coding RNAs, and 
15 microRNAs whose expression were uniquely altered in never smokers. Integrating the 
mRNA and microRNA data created a regulatory network for never smokers. We 
hypothesize that lung adenocarcinoma in never smokers compared to former and current 
smokers (ever smokers) have distinct microRNA regulators that may be leveraged to 
identify personalized lung cancer treatment options. By analyzing the integrative 
regulatory network, we identified miR-424 as a potential regulatory element in never 
smoker lung adenocarcinoma. MiR-424 was up-regulated in never smoker tumor, highly 
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connected as a regulatory hub in the network, and has been previously described as an 
oncomiR in other cancers
98,99
. Differential expression of miR-424 was validated by a 
secondary platform, qRT-PCR, and found to have no association with EGFR mutational 
status. Interestingly, miR-424 is more highly expressed in the small airways of never 
smokers compared to ever smokers, a result requires additional studies to explore the 
potential of a airway biomarker for never smokers. Knockdown of miR-424 in never 
smoker adenocarcinoma cell line H2085 followed by gene expression array profiling 
revealed perturbations in many cancer hallmark pathways, including a number of 
migration related pathways. Strikingly, the functional knockdown of potential oncomiR 
miR-424 in the H2085 cell line significantly reduced migration by a scratch assay and the 
overexpression of miR-424 in the non-migratory cell line SK-LU-1 significantly 
increased migration. Further characterizing these discoveries will help elucidate the 
molecular underpinnings that differ between lung adenocarcinoma in smokers and in 
never smokers. These studies may ultimately lead to novel therapeutic targets and airway 
biomarkers for lung adenocarcinoma in never smokers. 
1.7.3 Aim 3: MicroRNA 34c 5’ IsomiR Regulates Ras Signaling Genes in Interstitial Lung 
Disease 
 The molecular mechanisms of the pathogenesis of ILD are still being 
uncovered
100
. As part of the Lung Genomics Research Consortium (LGRC), we 
previously performed small RNA sequencing on lung tissue from patients with and 
without ILD. Differential expression analysis showed miR-34c as highly induced in ILD 
tissue, with reads mapping to not only the canonical microRNA sequence, but that of 5’ 
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and 3’ isomiRs as well. The purpose of this study was to validate differential expression 
of miR-34c in ILD compared to control tissue as well as characterize miR-34c and its 5’ 
isomiR by exploring their direct targets that are shared by both forms as well as direct 
targets that are specific to each variant. Predicted targets of miR-34c and the miR-34c 5’ 
isomiR were enriched for genes involved in Ras signaling, a group of genes that are 
involved in pathways such as the EGFR pathway, whose dysregulation is described as 
conferring susceptibility to ILD
101,102
. By transiently transfecting lung fibroblast cells, we 
show that the 5’ isomiR of miR-34c targets GRB2, an important early member of the 
RAS/EGFR pathway. In addition, the canonical miR-34c microRNA fails to 
downregulate GRB2, indicating specificity for the 5’ isomiR. These data highlight the 
effect a small variation in the canonical microRNA has on the ability of a microRNA to 
regulate gene expression as well as introduces a miR-34c 5’ isomiR as a potential 
therapeutic target for targeting the RAS/EGFR pathway.  
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CHAPTER TWO 
MicroRNA 4423 is Involved in Lung Epithelial Differentiation and its Expression is 
Lost with Lung Cancer Progression  
2.1 Introduction 
 The airway epithelium provides a barrier against inhaled toxins, frequently 
undergoing cell turnover to replace those cells that are damaged with the rate of turnover 
depending on the rate of injury 
5,13
. Repair occurs by multipotent basal cells migrating to 
the denuded area, proliferating and differentiating into the other airway cell types, such as 
ciliated, secretory and goblet cells 
103
. Ciliated cells in the airway epithelium are 
terminally differentiated 
104,105
 and as such it is believed that growth arrest is necessary 
for ciliated cell differentiation.  
MicroRNAs have been shown to play roles in many biological processes 
including apoptosis, proliferation and differentiation
12,53,60–65
. While microRNAs, such as 
miR-449 and miR-34, have previously been shown to play important roles in airway 
epithelial differentiation and development 
94,106,107
, the biological function of miR-4423, a 
recently discovered primate specific microRNA in the airway epithelium
96
, is unclear. 
Previous work shows that both the 5p and 3p forms of miR-4423 are expressed in organs 
with a mucociliary epithelium (Figure 2.1A), which include the airway and fallopian 
epithelium
96
. In addition, miR-4423 is expressed throughout the respiratory tract, with 
positive in-situ staining in the airway of the trachea, mainstem bronchus, and second 
generation bronchus (Figure 2.1B)
96
. Building upon the data previously generated, we 
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seek to evaluate the role of miR-4423 in differentiation of the normal airway epithelium 
using in-vitro manipulation of miR-4423 expression levels in an ALI system.  
 
Figure 2.1: The expression of miR-4423 is primarily restricted to mucociliary epithelium. Adapted from Perdomo 
et al. (A) Expression of both forms of miR-4423 across 24 human tissues is detected in the respiratory tract (lung, 
trachea, and nasal and bronchial epithelia), ovary, and fallopian tube epithelium. (B) By in situ hybridization, miR-
4423 is expressed in the epithelium of the trachea, mainstem bronchus, and second generation bronchus. Arrowheads 
point to the regions with positive staining. 
Disruption to the process of airway repair, including disruption of microRNAs 
can lead to many lung diseases such as lung cancer 
66,67
. In addition to being expressed in 
the airway epithelium, miR-4423 also inhibits tumor growth in-vitro and in-vivo
96
. 
Previous studies show that miR-4423 overexpression in “sensitive” cell lines prevents 
colony growth in soft agar (Figure 2.2A) and that in the H1703 SCC cell line, 
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overexpression of miR-4423 results in a decrease in xenograft tumor volume as well as 
tumor weight (Figure 2.2B)
96
. Phosphorylated E-cadherin staining in the H1703 
xenograft tumor tissue, shows positive staining in the miR-4423 overexpressing tumors, 
but not in the controls (Figure 2.2C), indicating an increase of cell-to-cell adhesions in 
the tumor and a possible mechanism for which miR-4423 is inhibiting tumor growth
96
.  
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Figure 2.2: MiR-4423 inhibits lung cancer anchorage-independent growth in vitro and tumor growth in vivo. 
Adapted from Perdomo et al. (A) Soft agar assays were performed in the indicated cell lines stably transfected with 
either a vector that overexpresses the miR-4423 precursor or the empty parent vector as a negative control (n=10). 
Overexpression of miR-4423 in four of the cell lines tested decreases the number of colonies formed in soft agar 
(CalU6, p = 2.8 x 10-7; SW900, p = 2.4 x 10-5; H1703, p = 7.4 x 10-9; RH2, p = 0.001). Error bars indicate SE, and p 
values were determined using Student t test. (B) H1703 (SCC) cells stably overexpressing miR-4423 or a control (1 x 
106) were injected subcutaneously into the backs of NSG mice (seven mice per group). Tumors derived from miR-4423 
overexpressing cells were growth-suppressed relative to the control-derived tumors as shown in representative 
photographs of the tumors (Left), tumor volume over time (p = 1.55 x 10-11) (Upper Right) and tumor weight (p = 0.01) 
(Lower Right). (C) Phosphorylated E-cadherin staining was performed in miR-4423-overexpressing tumors and 
controls (H1703). MiR-4423-overexpressing tumors exhibited focal areas of positive membrane phospho-E-cadherin 
staining consistent with the presence of adherens junctions (Lower). Phospho-E-cadherin staining was not observed in 
control tumors (Upper). Arrows point to regions of positive staining. 
Following the studies showing that miR-4423 is present in the airway epithelium 
and its expression in lung cancer cell lines inhibits tumor growth, we sought to explore 
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the role of miR-4423 in the differentiating airway epithelium and its expression with the 
progression of lung cancer.  
 
2.2 Results 
2.2.1 Expression of miR-4423 in an ALI culture 
 To better understand the expression of miR-4423 in the airway epithelium, an 
ALI culture system was used and HBEpCs were grown through a differentiation protocol. 
Looking at miR-4423 expression over time, both forms of the microRNA appear to be 
expressed starting around day six of an ALI culture with increased expression as the 
culture continues to differentiate (Figure 2.3).  
 By measuring the expression of airway cell type markers FOXJ1 (ciliated cells), 
K14 (basal cells), ASCL1 (neuroendocrine cells), MUC5AC (goblet cells), and CC10 
(secretory cells) we see that basal cells are continuously present in the culture with other 
cell type markers arising early in the differentiation process (Figure 2.4). Markers of 
ciliated cells appear to have the highest correlation with miR-4423 expression. WDR63, 
the transcript for a protein found in the inner dynein arm of cilia, is highly correlated with 
both miR-4423-5p (R=0.89) and miR-4423-3p (R=0.95). FOXJ1, which codes for a 
transcription factor in the nucleus of ciliated cells, is similarly correlated with miR-4423-
5p (R=0.9) and miR-4423-3p (R=0.93; Figure 2.5). Both these genes and arms of miR-
4423 are induced around day six and have increased expression throughout the 
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differentiation process. 
 
Figure 2.3: MiR-4423 expression during normal differentiation at an ALI. Basal cells underwent an ALI 
differentiation protocol over a period of 20 days with (n=2) inserts collected at each time point. Expression of miR-
4423-5p and miR-4423-3p first appears around day six of differentiation and continues to increase during the protocol 
duration, reaching a plateau around day 15.  
 
Figure 2.4: Cell type markers for all large airway cell types can be measured at an ALI. Basal cells underwent an 
ALI differentiation protocol over a period of 14 days with (n=3 to n=6) inserts collected at each time point in two 
experimental batches. Expression of FOXJ1 (ciliated cells), K14 (basal cells), ASCL1 (neuroendocrine cells), MUC5AC 
(goblet cells), and CC10 (secretory cells) is measurable during the differentiation process, highlighting the utility of an 
ALI as a biological model of the airway epithelium. 
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Figure 2.5: Cell type markers of ciliated cells most highly correlate with miR-4423 expression at an ALI. 
Pairwise spearman correlations between miR-4423-5p, miR-4423-3p, and the airway cell type markers ASCL1 
(neuroendocrine cells), FOXJ1 & WDR63 (ciliated cells), CC10 (secretory cells) and MUC5B & MUC5AC (goblet 
cells) show the highest correlation between miR-4423 and the ciliated cell markers. Correlations are shown using a 
hierarchical clustering matrix with higher correlation coefficient indicated by the color red. 
2.2.2 Constitutive miR-4423 overexpression induces ciliated cell production 
 HBEpCs infected with a constitutively active miR-4423 lentivirus show high 
levels of both miR-4423-5p (Figure 2.6A) and miR-4423-3p (Figure 2.6B) throughout all 
time points of the ALI differentiation process. All gene expression is normalized to eGFP 
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expression to account for any transduction efficiency differences between batches. 
Measuring markers of the cell types in an airway epithelium after basal cells 
overexpressing miR-4423 differentiate at an ALI, we see that FOXJ1 expression is 
increased with miR-4423 overexpression compared to control cultures (p<0.005; Figure 
2.7). Looking closely at FOXJ1 in the ALI inserts from the miR-4423 overexpression 
experiments by staining for FOXJ1 with immunofluorescence, we see that there are an 
increased number of cells expressing the ciliated cell nuclear marker at day 11 of the 
differentiation process (Figure 2.8). Staining for IV-tubulin, marking the cilia of ciliated 
cells, we see an increased number of cells in miR-4423 overexpressing ALI cultures 
staining positive (Figure 2.9) at day 11. These results indicate that miR-4423 expression 
induces ciliated cell production during differentiation at an ALI. 
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Figure 2.6: Overexpression of miR-4423 is measurable at an ALI. Basal cells infected with a lentivirus 
constitutively overexpressing miR-4423 successfully express (A) miR-4423-5p and (B) miR-4423-3p at a high level 
during the ALI differentiation protocol compared to control basal cells infected with an empty vector. Two ALI batches 
were normalized together with a total of n=2 to n=4 samples per time point. 
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Figure 2.7: Ciliated cell marker FOXJ1 expression is increased with overexpression of miR-4423. Basal cells 
infected with lentivirus constitutively overexpressing miR-4423 show a higher overall expression of FOXJ1 during the 
differentiation protocol at an ALI (p<0.005). Two ALI batches were normalized together with a total of n=2 to n=4 
samples per time point. 
 
Figure 2.8: Ciliated cell marker FOXJ1 staining is increased with overexpression of miR-4423. Basal cells 
infected with lentivirus constitutively overexpressing miR-4423 show more cells with nuclear staining of FOXJ1 at day 
11 of the differentiation protocol at an ALI compared to control. DAPI is shown in blue, FOXJ1 is shown in red, and 
green is present from autofluorescence of the ALI membrane as well as from the lentivirus used to infect the cells. 
Arrows point to regions of positive co-localization of DAPI and FOXJ1 staining. Images are at 10x magnification. 
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Figure 2.9: Cilia marker IV-tubulin staining is increased with overexpression of miR-4423. Basal cells infected 
with lentivirus constitutively overexpressing miR-4423 show more patches of cilia staining for IV-tubulin at day 11 of 
the ALI differentiation protocol compared to control. Arrows point to regions of positive staining. 
2.2.3 Attempted knockdown of miR-4423 is not sufficient to modulate FOXJ1 expression 
in ALI cultures 
 Knock down of both forms of miR-4423 at the same time with a constitutive 
lentivirus  did not affect the gene expression levels of miR-4423, preventing us from 
measuring the efficiency of the lentivirus in our ALI system. Determining that miR-4423 
maybe suppressed and not degraded, we measured the expression of FOXJ1 to determine 
if loss of miR-4423 results in a change in the ciliated cell population. No significant 
change in FOXJ1 expression was seen with our attempted miR-4423 knockdown (Figure 
2.10). 
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Figure 2.10: Ciliated cell marker FOXJ1 expression is not changed with miR-4423 knockdown. Basal cells 
infected with lentiviruses containing antimirs to miR-4423-5p and miR-4423-3p were run on an ALI in two batches. 
RNA was collected from both batches at multiple time points until day 17 of the differentiation protocol (n=2 to n=6 
per time point). No significant difference was observed in the expression of ciliated cell marker FOXJ1 between the 
control and knockdown samples. 
2.2.4 Expression of miR-4423 is diminished with the presence of cancer 
 With previous work in the lab showing a field of injury in the airway epithelium 
that can be used to identify lung cancer in distal regions of the lung
25
 we wanted to 
measure miR-4423 expression in the airway epithelium of patients with and without 
cancer. Bronchoscopy brushings from patients without cancer had a higher expression of 
both miR-4423-5p (p<0.05) and miR-4423-3p (p<0.05; Figure 2.11) than brushings from 
patients with lung cancer. Similarly, when we measure miR-4423 expression in one 
patient’s samples with increasing severity of disease, starting with laser captured normal 
airway epithelium, followed by samples of laser captured squamous metaplasia and SCC, 
we see that miR-4423 expression decreases with increasing disease severity (Figure 
2.12).  
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 Moving from the airway to connect to data previously seen with miR-4423’s 
ability to be a tumor suppressor, we measured miR-4423 expression in SCC tumor tissue 
as well as in the adjacent histologically normal tissue. We see that miR-4423-5p (p<0.05) 
and miR-4423-3p (p<0.05) expression is lost with disease (Figure 2.13).  
 
Figure 2.11: Expression of miR-4423 in the histologically normal large airway of patients with lung cancer is 
lower than that of patients without cancer. Bronchial brushings of histologically normal airway from patients with 
(n=7) and without (n=4) lung cancer were collected and processed for RNA. Patients with lung cancer have 
significantly lower expression of miR-4423-5p (p<0.05) and miR-4423-3p (p<0.05) then patients without lung cancer. 
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Figure 2.12: Expression of miR-4423 is decreased with increasing disease severity. The expression of miR-4423-5p 
and miR-4423-3p was measured in laser captured histologically normal airway (n=2-3), laser captured squamous 
metaplasia (n=1) and SCC (n=2-3) from a resected lung of one patient. Expression of miR-4423 decreases with 
increasing disease severity: from normal to squamous metaplasia and from squamous metaplasia to SCC.  
 
Figure 2.13: Expression of miR-4423 is decreased in tumor tissue compared to adjacent normal tissue. Tumor 
and adjacent normal tissue from patients with SCC (n=11) were measured for miR-4423 expression. The expression of 
miR-4423-5p (p<0.05) and miR-4423-3p (p<0.05) was significantly lower in tumor tissue compared to paired normal 
tissue. 
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2.2.5 Potential targets of miR-4423 in tumor cells are not necessarily the same as those 
in the airway epithelium 
 In an attempt to identify direct targets of miR-4423, microarray data previously 
produced in our lab of cancer cell lines sensitive to miR-4423 overexpression (CalU6 and 
SW900) that were infected with a constitutive miR-4423 lentivirus or an empty vector
96
 
were mined for genes whose expression was significantly decreased with miR-4423 
overexpression. A total of 148 predicted targets of miR-4423 were found to be 
significantly decreased (p<0.05) in the CalU6 cell line and 788 predicted targets of miR-
4423 were significant (p<0.05) in the SW900 cell line. Between the two cell lines, there 
were 58 potential targets in common. To narrow down the list of 58 genes, we used 
WDR63 as a surrogate marker of miR-4423. A RNA sequencing dataset of ALI inserts 
over time was mined to identify the correlation of the 58 genes with WDR63, looking for 
genes that are significantly anti-correlated with WDR63 (p<0.05; Figure 2.14). From 
there, eleven genes were identified as potential direct targets of miR-4423 (Figure 2.15). 
Three genes of the eleven were chosen as interesting potential targets of miR-
4423 for follow-up studies based on the known biology of the proteins they code for. 
UBE4B is an ubiquitination factor that monoubiquitinates the tumor suppressor p53 on its 
own or polyubiquitinates p53 with the help of MDM2
108–110
. KLK10 belongs to a 
subgroup of serine proteases known as kallikreins. The expression of KLK10 is increased 
in gastric and colorectal cancer
111,112
 while other kallikreins are known to be promote loss 
of cell-cell junction integrity
113–115
. LRP8 is a member of the low density lipoprotein 
receptor family that is involved in the Wnt pathway
116
 and is a driver of cancer 
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metastasis
117,118
. Known roles in cancer and/or differentiation pathways make UBE4B, 
KLK10, and LRP8 primary targets of interest for direct targets of miR-4423.  
 Measuring the expression of these three genes in cancer cell lines with miR-4423 
overexpression, we see that UBE4B expression is reduced in CalU6, SW900 and 
SKMES1 cell lines (Figure 2.16A). KLK10 is not endogenously expressed in CalU6, 
RH2 or H1299 cell lines but in SW900, expression is reduced with miR-4423 
overexpression (Figure 2.16B). LRP8 expression is reduced in CalU6 and SW900 cell 
lines with miR-4423 overexpression (Figure 2.16C). The two cell lines used to identify 
potential targets, CalU6 and SW900, show a reduction in the three genes expression with 
miR-4423 overexpression, but the other cell lines are varied in response. 
In ALI samples with miR-4423 constitutively expressed, UBE4B (Figure 2.17A), 
KLK10 (Figure 2.17B), and LRP8 (Figure 2.17C) show no significant difference in 
expression throughout the differentiation process between miR-4423 overexpressing cells 
and control cultures. While these genes may be direct targets of miR-4423 in tumor cells, 
they appear to not be affected by miR-4423 expression in the airway epithelium.  
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Figure 2.14: Workflow used to identify potential miR-4423 direct targets. All genes identified in bold are 
significant (p<0.05). 
 
Figure 2.15: Eleven genes are identified in ALI sequencing dataset as anticorrelated to WDR63 expression. The 
ALI sequencing dataset is comprised of samples collected at multiple time points throughout the ALI differentiation 
process with six different donor HBEpCs. Time point during the ALI differentiation process is represented in the color 
bar at the top of the heatmap with increasing green color with increasing time at an ALI. Using WDR63 as a surrogate 
for miR-4423 expression, eleven genes were narrowed down from the 58 genes identified as predicted targets of miR-
4423. These eleven genes are significantly anticorrelated to WDR63 expression at an ALI (p<0.05) and are listed in the 
heatmap based on the strength of their anticorrelation with genes at the top more anticorrelated. Correlations were 
determined using Pearson correlations. 
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Figure 2.16: Expression of potential direct targets of miR-4423 in cell lines overexpressing miR-4423. Three cell 
lines that previously showed a decrease in soft agar colonies with miR-4423 overexpression (CalU6, SW900, and RH2) 
as well as two cell lines that had no change in soft agar (H1299 and SKMES1) were measured for (A) UBE4B, (B) 
KLK10, and (C) LRP8 expression. All three genes show downregulation with miR-4423 overexpression, when the gene 
is expressed, in the sensitive cell lines CalU6 and SW900.  
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Figure 2.17: Expression of potential direct targets of miR-4423 in ALI cultures overexpressing miR-4423. The 
expression of the three predicted direct targets of miR-4423 was measured at an ALI overexpressing miR-4423. Basal 
cells infected with lentivirus constitutively overexpressing miR-4423 show no difference in gene expression of (A) 
UBE4B, (B) KLK10, and (C) LRP8 compared to control ALI. Two ALI batches were normalized together with a total 
of n=3 to n=4 samples per time point.  
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2.3 Materials and Methods 
Air-Liquid Interface Cultures 
 Cells used in cultures were obtained from the National Disease Research 
Interchange (Philadelphia, PA) after a protocol obtained by their IRB was approved. 
HBEpCs obtained from three donors (two 23-year-old and one 13-year-old nonsmoking 
Caucasian males) were plated onto collagen coated tissue culture inserts (Millipore Corp., 
New Bedford, MA) and grown in submerged conditions in BEGM (Lonza, Walkerville, 
MD) until confluent. Media in the apical chamber was then removed to allow ALI 
growth. Media in the basolateral chamber was replaced every other day for up to 21 days 
to allow full differentiation with ALI medium (MatTek Corporation, Ashland, MA) 
containing insulin (5mg/mL), transferrin (5mg/mL), hydrocortisone (0.5nM), bovine 
pituitary extract (26mg/mL), EGF (0.6ng/mL), epinephrine (0.5ng/mL), all-trans retinoic 
acid (50nM), penicillin (100u/mL) and streptomycin (100mg/mL). Cultures were fixed in 
paraffin sections for evaluation of morphology or placed in RNALater (Ambion, Foster 
City, CA) until RNA could be isolated. 
qRT-PCR 
To measure the expression of miR-4453-3p and miR-4423-5p, 10ng of total RNA 
was used in a custom Taqman MiRNA Assay (Life Technologies, ID #CCBI832, 
CSFAQ5N, Carlsbad, CA) as per manufacturer’s protocol and the results were 
normalized to RNU44 expression (Life Technologies, Catalog #4427975, ID #001094, 
Carlsbad, CA). The expression of UBE4B, KLK10, and LRP8 was measured using 500 
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ng total RNA with the High-Capacity cDNA Reverse Transcription Kit (Life 
Technologies, Catalog #4368814, Carlsbad, CA) according to the manufacturer’s 
protocol. cDNA product was added to Taqman Fast Universal PCR Master Mix (Life 
Technologies, Catalog #4352042, Carlsbad, CA) and the appropriate Taqman Gene 
Expression Assay (Life Technologies, Catalog #4331182, ID #Hs00195897_m1, 
Hs00173611_m1, Hs00182998_m1, Carlsbad, CA). Data was normalized to the 
expression of GAPDH (Life Technologies, Catalog #4331182, ID #Hs02758991_g1, 
Carlsbad, CA) and analyzed using the comparative CT method. The expression of 
FOXJ1, MUC5AC, MUC5B, CC10, ASCL1, WDR63, and GAPDH were measured by 
reverse transcribing total RNA using random hexamers (Life Technologies, Carlsbad, 
CA) and Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA). A total of 20ng 
of cDNA product was then added to SYBR Green PCR master mix (Life Technologies, 
Carlsbad, CA) and the relevant primer (IDT, Coralville, IA) for qRT-PCR. Data were 
normalized to GAPDH expression and analyzed using the comparative CT method. 
Primers were designed as follows: 
FOXJ1: 
For: 5’-GGA GGG GAC GTA AAT CCC TA-3’ 
Rev: 5’-CCA AAC TTC CAG CTG CTC TC-3’ 
MUC5AC: 
For: 5’-CTG GGA GTC CAG GTC ATG TT-3’ 
Rev: 5’-TGT TGG CAA ACT TGC TGA AG-3’ 
MUC5B: 
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For: 5’-GAC CTG CAA GAA CGA AGA CC-3’ 
Rev: 5’-AAA GCA CAC GCA CGT TGT AG-3’ 
CC10: 
For: 5’-GCT CAG CTG AAG AAG CTG GT-3’ 
Rev: 5’-TGA TGC TTT CTC TGG GCT TT-3’ 
ASCL1: 
For: 5’-GAG CAA CTG GGA CCT GAG TC-3’ 
Rev: 5’CTT TTG CAC ACA AGC TGC AT-3’ 
WDR63: 
For: 5’-GCT GGG AAT AAG CCA CAC AT-3’ 
Rev: 5’-GAG AGT CCC CCT CTC TGC TT-3’ 
eGFP: 
For: 5’-GAC GTA AAC GGC CAC AAG TT-3’ 
Rev: 5’-GAA CTT CAG GGT CAG CTT GC-3’ 
K14: 
For: 5’-GGC CTG CTG AGA TCA AAG AC-3’ 
Rev: 5’-TCC TCA GGT CCT CAA TGG TC-3’ 
GAPDH 
For: 5’-TGC ACC ACC AAC TGC TTA GC-3’ 
Rev: 5’-GGC ATG GAC TGT GGT CAT GAG-3’ 
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Stable Cell Line Production 
 The DNA sequence with the miR-4423 precursor and approximately 200bp of 
flanking region was amplified by PCR using primers (IDT: Forward 5’-
CGCGGATCCACACAGCTCACACCATCAGG-3’ and Reverse 
5’-CGCGGATCCCATGAGACTCTCCCCTGCTC-3’, Coralville, IA). The fragment was 
then ligated into the BamHI restriction site of the phage-CMV-eGFP-W plasmid. 
Plasmids containing miR-4423 or an empty vector were transfected into 293T cells along 
with expression vectors containing the packaging proteins Gag-Pol, Rev, Tat and VSV-G. 
Viral particles in the supernatants were collected and concentrated using 
ultracentrifugation. Cancer cell lines were grown in 24-well plates and lentiviral infection 
was performed when cells were 40-50% confluent. HBEpCs (MatTek, Ashland, MA) 
were cultured on collagen-coated dishes in serum-free BEGM medium (Lonza, 
Walkersville, MD) to generate stable cells overexpressing miR-4423 or empty vector. 
Cells were infected with virus particles that were diluted in antibiotic-free BEGM 
medium with 4ug/mL SureENTRY (Qiagen, Valencia, CA) at an MOI of 20 at 50-60% 
confluence for 24 hours. To generate HBEpCs with miR-4423 stably knocked-down, 
primary passage cells were co-infected with both miR-4423-3p and miR-4423-5p miRZip 
anti-microRNA expression lentivectors or a scramble control (System Biosciences, 
Mountain View, CA) with an MOI of 20 for each lentivector. 
Cell Staining 
 To prepare ALI samples for staining, EpiAirway tissues (MatTek, AIR-100, 
Ashland, MA) were fixed in formalin at room temperature overnight followed by 
  35 
embedding in paraffin and sectioning onto slides. Sections were then deparaffinized in 
Xylene and graded alcohol washes for rehydration. Heat mediated antigen retrieval was 
performed by incubating slides in 0.01M Sodium Citrate buffer, pH 6.0, for 45 minutes at 
100°C. For FOXJ1 staining, slides were blocked in 10% normal goat serum plus 1% BSA 
in PBS for one hour followed by incubation with anti-FOXJ1 primary antibody (abcam, 
ab40869, Cambridge, MA) at 1:4000 dilution with 1% BSA in PBS at 4°C overnight. 
Slides were washed and incubated in Alexa Fluor conjugated secondary antibody (Life 
Technologies, Carlsbad, CA) at a 1:400 dilution for one hour at room temperature. 
Sections were imaged using an Olympus FluoView FV1000 confocal microscope. Image 
analysis and quantification were performed using Nikon NIS Elements software. For IV-
Tubulin staining, Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA) was 
used according to the manufacturer’s protocol. Sections were incubated in mouse anti-
IV-Tubulin (BioGenex, San Ramon, CA) diluted at 1:1500 with 1% BSA in PBS for one 
hour at room temperature. Slides were washed and incubated in biotinylated secondary 
antibody for 30 minutes at room temperature and subsequently incubated for 30 minutes 
with ABC reagent. Staining was completed with the Vector DAB substrate kit (Vector 
Laboratories, Burlingame, CA), which was prepared according to the manufacturer’s 
instructions. Slides were incubated in the solution for 5-10 minutes at room temperature 
followed by a wash with dH2O and a counterstain with Mayer’s Hematoxylin before 
being coverslipped. Imaging was done with a Nikon Eclipse Ti inverted microscope.  
  36 
2.4 Discussion 
 The discovery of the novel primate-specific microRNA miR-4423 led to studies 
showing miR-4423 is only expressed in mucociliary epithelium and has the ability to 
inhibit cancer cell growth with forced expression of miR-4423 in some cancer cell lines
96
. 
Expanding on these studies, we have further characterized miR-4423’s role in airway 
epithelium differentiation and its loss of expression with the progression of lung cancer.  
 The differentiation of lung airway epithelium is regulated by a number of 
microRNAs
94,106,107
. For this reason, the study of microRNAs in the airway epithelium is 
important to better understand the endogenous procedure that basal cells undergo to 
differentiate into a complete epithelium. By better understanding this process, we can 
expand our ability to treat many common disease that arise from abnormal airway 
epithelium, such as asthma, chronic obstructive pulmonary disease and potentially even 
lung cancer
4,27,103
. The work done in this study characterizes a newly discovered 
microRNA in the airway epithelium by utilizing an ALI culture system. We show that 
expression of miR-4423 is increased during the basal cell differentiation process, with 
little to no expression in basal cells themselves, and that the endogenous expression of 
miR-4423 closely correlates with expression of ciliated cell markers FOXJ1 and WDR63. 
Additionally, when miR-4423 is stably overexpressed in basal cells, we see an increase in 
ciliated cells during the differentiation process. These results indicate miR-4423 plays a 
role in promoting ciliogenesis. After attempting to knockdown miR-4423 we see no 
change in gene expression of FOXJ1 and no phenotype change in the airway epithelium, 
implying that knocking down miR-4423 is not sufficient to alter ciliogenesis in the 
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airway epithelium. With miR-4423 being a primate-specific microRNA, it’s possible that 
it plays a redundant role and that there are other family members that can compensate for 
loss of miR-4423. Indeed, the miR-34/449 family has members whose seed sequences are 
close to those of miR-4423
96
 and this family is very well characterized as being 
evolutionarily conserved and important in ciliogenesis in the airway epithelium
94,107,119
. 
 Expanding on studies showing miR-4423’s potential role as a tumor suppressor in 
lung cancer
96
, as well as previous work showing a field of injury in the airway of patients 
with lung cancer
25
, we measured miR-4423 expression in histologically normal airway 
epithelium of patients with and without lung cancer. The expression of both forms of 
miR-4423 is diminished in the airway of patients with lung cancer, implying that miR-
4423’s loss of expression indicated a microRNA field of injury for cancer. Moving out of 
the airway and into premalignancy, we measured miR-4423 expression in laser captured 
sections of one patient’s normal airway, squamous metaplasia and SCC tissue. While the 
sample numbers are small and only representative of one patient, it appears that the 
expression of miR-4423 is gradually lost with increasing disease. When looking at miR-
4423 expression in tumor compared to adjacent histologically normal tissue, there is a 
significant loss of miR-4423 expression in SCC tissue compared to normal tissue. All of 
these results indicate a true loss of miR-4423 expression with the development of lung 
SCC and reinforce the concept of miR-4423 as a tumor suppressor.  
 With miR-4423 playing a role in promoting ciliogenesis and acting as a tumor 
suppresser when there is forced expression in the tumor cells, it stands to reason that the 
mechanism by which miR-4423 promotes differentiation is the same as the mechanism in 
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which it inhibits cell growth in tumors. With the cell of origin for squamous cell 
carcinoma not believed to be ciliated cells, we can postulate that loss of miR-4423 in 
ciliated cells is not a driver of lung cancer, but a consequence. Preliminary analysis of 
predicted targets of miR-4423 in our datasets, has not identified a shared mechanism for 
ciliated cell differentiation and cancer inhibition with miR-4423 expression. Three genes 
that may play a role in miR-4423’s ability to hinder tumor growth do not appear to be 
altered with miR-4423 overexpression at an ALI. A better understanding of miR-4423’s 
mechanism of action in tumor and airway phenotypes is necessary for further research 
into miR-4423’s potential as a cancer therapeutic. 
 This study is not without limitations. All ALI cultures have a large batch affect, 
making it hard to combine experiments. In addition, while we can measure the 
overexpression of miR-4423 in cell culture, the knockdown of miR-4423 does not 
degrade the microRNA, meaning that by qRT-PCR we are unable to measure the 
knockdown efficiency and can only rely on being able to measure transfection efficiency 
of the lentiviruses via GFP expression in the cells. Future work will need to be done to 
uncover the mechanism of action for miR-4423 in ciliogenesis as well as its role in 
suppressing tumor growth.  
 
2.5 Conclusions 
The research put forth in this study clearly shows a role for miR-4423 in airway 
epithelial differentiation. Moreover, we show that miR-4423 expression is gradually lost 
with increasing disease severity in relation to SCC. These findings as well as work 
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previously done in our lab showing miR-4423’s ability to suppress cancer growth96, 
indicate a potential for miR-4423 to be utilized as a therapeutic for SCC. Further research 
is needed to determine if miR-4423 intervention can reverse early events in 
carcinogenesis, such as premalignant lesions. The mechanism of action for miR-4423 in 
regards to its ability to promote ciliogenesis as well as its ability to suppress tumor 
growth needs to be better understood, whether there is a common mechanism for both 
phenotypes or individual pathways that are affected based on the biological context, 
remains to be seen. Finally, the characterization of this microRNA in the airway 
epithelium highlights the need to better understand the role of microRNAs in normal 
biological processes so that we can better understand their part in disease progression and 
how they can be utilized as therapeutics.  
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CHAPTER THREE 
MicroRNA 424 is a Potential OncomiR in Never Smoker Lung 
Adenocarcinoma that Regulates Cell Migration  
3.1 Introduction 
While the leading cause of lung adenocarcinoma is cigarette smoke exposure, 10-
15% of lung adenocarcinoma cases in the US occur in patients who have never 
smoked
120
. Lung cancer in never smoker patients is the seventh leading cause of all 
cancer mortality and the top cancer related cause of death of never smokers in the US
39,97
. 
Outside the US, never smoker lung cancer rates are highest in China and appear to be on 
the rise in a number of countries including: Japan, Sweden, Italy and the United 
Kingdom
121
. The incidence of lung cancer amongst never smokers in the United States 
continues to rise annually
122
. 
Recent studies have indicated that lung cancer patients who are either ever 
smokers (>100 cigarettes in their lifetime) or never smokers harbor distinct profiles of 
somatic mutations, and that these two groups elicit disparate responses to targeted 
therapy
123,124
. For example, EGFR mutations are present in 45% of never-smoker lung 
adenocarcinomas but only 7% of ever-smoker lung adenocarcinomas, and can be 
exploited for targeted therapy with EGFR-TKI (Tyrosine Kinase inhibitors)
40
. Although 
the use of EGFR-TKI offers therapeutic benefits to some patients with late stage 
adenocarcinoma, many develop resistance to EGFR-TKI, rendering the use of this 
therapeutic limited
125
. This supports the need for further molecular characterization of 
never smoker lung cancer to develop novel therapeutics. In addition, a number of 
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molecular abnormalities including TP53 mutations, KRAS mutations, chromosomal 
aberrations, and unique gene expression and methylation profiles, have been identified to 
vary between the lung tumors of never smokers and ever smokers suggesting that there 
exist unique molecular drivers that require further characterization
126–128
.  
Previously we performed large and small RNA sequencing on paired 
adenocarcinoma and adjacent histologically normal tissue from ever and never smokers. 
Linear modeling revealed 120 large RNA (Figure 3.1A) and 15 microRNA (Figure 3.1B) 
uniquely changing in never smokers. 
 
Figure 3.1: Large and small RNA sequencing identifies never smoker tumor-specific transcriptomic 
perturbations. (A) Semi-supervised heatmap of 120 genes whose expression levels vary uniquely between tumor and 
adjacent-normal samples in never smokers. Differential expression analysis was conducted using the same linear mixed 
effect models and filters as implemented for the microRNA data. Each row represents one of 120 genes, and each 
column represents one of 44 tumor and adjacent normal samples collected from 22 subjects. Blue represents lower 
relative expression, and red represents higher relative expression. (B) Semi-supervised heatmap of 15 microRNAs 
whose expression levels vary uniquely between tumor and adjacent-normal samples in never smokers. Using the same 
differential expression strategy as for large RNA, linear modeling identified 15 microRNAs that appear to be uniquely 
modulated in the never smoker tumor. 
To gain insight into the regulation of never smoker lung cancer, mirConnX was 
used to build a regulatory network
129
. This network contains 7 microRNAs (miR-424, 
miR34a, miR-500, miR-1260, miR-652, miR-324, miR-146b) connected to 519 protein 
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coding genes, 18 of which are transcription factors, for a total of 591 interactions (Figure 
3.2). 
 
Figure 3.2: Tumor-associated microRNA-mRNA network constructed from never smoker sequencing results 
implicates miR-424-5p as a regulatory hub. The 15 microRNAs that were predicted to be associated with never 
smoking adenocarcinoma were integrated with gene expression data from matching samples to construct a microRNA-
mRNA regulatory network (mirConnX). After overlaying the filtered expression data with a prior network of putative 
target predictions, we computed a network comprised of 591 interactions, which includes 7 microRNAs (squares) 
exhibiting suppressive interactions with 501 protein-coding genes (circles) and 18 transcription factors (triangles). One 
microRNA, miR-424-5p (circled in yellow) was identified as a major regulatory hub and selected for further analysis. 
Node colors reflect the relative high (red) or low (blue) T/N expression of each mRNA or microRNA as calculated by 
the T statistic generated from a Student’s t test. 
Through the combination of RNA sequencing and integrative transcriptomic 
network analysis, potential microRNA regulators of never smoker lung adenocarcinoma 
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are revealed. Further functional validation and molecular biology are needed to parse 
down the list of seven microRNAs and identify the phenotypes affected by their 
overexpression in tumor tissue. Extending the studies presented, we sought to explore the 
microRNA regulation of never smoker lung adenocarcinoma. 
 
3.2 Results 
3.2.1 Identification of miR-424 as a potential regulatory element of never smoker lung 
adenocarcinoma 
One microRNA, miR-424, was highly connected in this network (with 218 
connections) and inconsistently expressed in the tumors of ever smokers compared to 
paired adjacent normal tissue (Figure 3.3A), while it was expressed higher in tumor tissue 
compared to paired adjacent normal in individual never-smoker patients (Figure 3.3B).  
The 218 genes connected to miR-424 in the mirConnX network (Table 3.1) were 
further analyzed for function enrichment using a pathway analysis tool called Enrichr
130
. 
Many cancer-related pathways were identified as significantly represented in our list of 
genes, including: regulation of cell adhesion (p<0.000005), regulation of epithelial cell 
migration (p<0.0005), and PI3K/AKT signaling in cancer (p<0.005; Table 3.2). 
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Figure 3.3: Dynamics of RNA sequencing miR-424 expression in individual patients. The paired tumor and 
adjacent normal RNA sequencing expressions are represented with red indicating higher expression in the tumor than 
adjacent-normal and blue indicating lower expression in the tumor than adjacent-normal in (A) ever smokers with lung 
adenocarcinoma (n=17) and (B) never smokers with lung adenocarcinoma (n=14). 
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Table 3.1: Genes that are connected to miR-424-5p node in the mirConnX network. 
 
Table 3.2: Enrichr analysis of genes predicted to be targets of miR-424-5p in the mirConnX network. 
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3.2.2 Validation of miR-424 expression 
The potential regulatory hub miR-424-5p and transcription factor, FOXP2, were 
identified from the RNA sequencing data and constructed networks as being uniquely 
altered in the tumor versus adjacent-normal tissue of never smokers as compared to ever 
smokers. The behavior of these genes was subsequently validated by qRT-PCR using a 
composite of adenocarcinoma tumor and adjacent-normal samples from an independent 
sample set and remaining RNA from the original sample set analyzed together (10 
current, 22 former, 20 never; Table 3.3). MiR-424 fold change in paired tumor and 
adjacent normal samples is significantly different between never and ever smokers in the 
RNA sequencing data (p<0.005; Figure 3.4A). The difference seen is recapitulated by 
qRT-PCR (p<0.05; Figure 3.4B). Similarly, FOXP2 is downregulated in the tumors of 
never smokers compared to ever smokers in the RNA sequencing data (p<0.05; Figure 
3.5A) and validates by qRT-PCR (p<0.05; Figure 3.5B).  
EGFR mutational status of the independent sample set (Table 3.4) was known and 
miR-424-5p expression shows no significant difference in ever smokers (p=0.74) and 
never smokers (p=0.87) based on mutation status (Figure 3.6).  
Previous work in the lab shows a field of injury in the airway epithelium that can 
be used to identify lung cancer in distal regions of the lung
25
. We wanted to measure 
miR-424 expression in the airway epithelium to explore the possibility of a field in never 
smokers. The expression of miR-424-5p was measured by qRT-PCR in cytologically 
normal small airway samples from patients with lung adenocarcinoma (5 current, 14 
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former, 14 never; Table 3.4). We observed higher expression of miR-424 in the small 
airways of never-smokers compared to ever-smokers (p<0.05; Figure 3.7).  
 
Table 3.3: Cohort of clinical samples used for qRT-PCR validations. 
 
Figure 3.4: MiR-424-5p expression by microRNA sequencing is validated by qRT-PCR. (A) Comparison of tumor 
and adjacent normal expression levels for miR-424-5p as detected by microRNA sequencing. log2 FPKM of miR-424 
in the paired tumor and adjacent-normal microRNA sequencing data was used to calculate fold change (FC). Never 
smoker paired samples demonstrate significantly higher expression of miR-424 in tumor versus adjacent normal than 
the ever smoker paired samples (never smoker tumor vs. adjacent normal p-value<0.0005). (B) qRT-PCR results 
indicating miR-424 expression levels in tumor versus adjacent normal samples from a cohort of previously sequenced 
and independent samples. miR-424-5p expression levels in tumor versus adjacent normal samples from never smokers 
(n=20) demonstrate significant two-fold increase (p<0.05) compared to levels in tumor versus adjacent normal of ever 
smokers (n=32). 
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Figure 3.5: FOXP2 expression by large RNA sequencing is validated by qRT-PCR. (A) Expression of FOXP2 in 
the paired tumor and adjacent-normal large RNA sequencing data was used to calculate FC. Never smoker paired 
samples show significantly lower (p<0.05) expression of FOXP2 in tumor vs. adjacent-normal then the ever smoker 
paired samples. (B) qRT-PCR of ever (n=32) and never (n=20) paired tumor and adjacent-normal samples show a 2-
fold decrease in FOXP2 expression levels in the tumor of never smokers compared to their adjacent-normal, a 
significant decrease compared to ever smokers (p<0.005).  
 
Table 3.4: Cohort of clinical samples used for EGFR and small airways qRT-PCR studies. 
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Figure 3.6: MiR-424-5p expression is not affected by EGFR status. EGFR status of samples from MD Anderson 
Cancer Center (n=5 currents, 14 formers, 14 never smokers) was identified and miR-424 FC was plotted based on 
status. No significant differences were observed.  
 
Figure 3.7: Expression of miR-424-5p is higher in the small airway of never smokers with lung adenocarcinoma 
compared to ever smokers. miR-424-5p was measured in small airways samples from the same patients that paired 
tumor and adjacent normal were obtained from at MD Anderson Cancer Center (n=5 currents, 14 formers, 14 never 
smokers). miR-424-5p expression was highly expressed in the small airways of never smokers compared of those of 
ever smokers (p<0.05). 
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3.2.3 Pathway enrichment of perturbing miR-424 in never smoker lung cancer cell line 
To characterize the transcriptomic changes induced by miR-424-5p perturbation, 
we profiled gene expression in the never-smoker lung adenocarcinoma cell line H2085 
transfected with either an inhibitor of miR-424-5p (n=3) or a control inhibitor (n=3) using 
microarrays. All profiled genes were organized into a ranked list by t-statistic and tested 
for enrichment of the mirConnX-predicted miR-424 targets from the regulatory network. 
GSEA revealed statistically significant positive enrichment of this set of genes (p<0.05), 
confirming mirConnX’s ability to predict association between a microRNA and its 
targets. We probed the leading edge of this analysis for enriched pathways. The leading 
edge results indicated that miR-424-5p might be regulating migration, angiogenesis, and 
cell adhesion in our never-smoker lung adenocarcinoma cell line (Table 3.5). 
 
Table 3.5: Enrichr analysis of genes in the mirConnX/microarray GSEA leading edge. 
3.2.4 Potential targets of miR-424  
 The identification of potential targets of miR-424 required numerous steps. To 
begin with, a list of predicted targets of miR-424 from TargetScan
131
 were compared to 
the 882 genes significantly upregulated with miR-424 knockdown as measured in our 
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microarray analysis (Figure 3.8). From there, the 154 genes identified were compared to 
the genes interacting with miR-424 in the mirConnX map. A total of ten genes fit all the 
filtering criteria (Table 3.6). Of interest for possible follow-up studies, DNAJB4 is 
reported to post transcriptionally influence E-cadherin localization and stability, making 
it a potential tumor suppressor
132
. TMEM100 is downregulated in lung adenocarcinoma 
and in-vitro studies show that overexpression of TMEM100 inhibits colony formation in 
lung cancer cell lines
133
. Additionally, TMEM100 is published as a potential tumor 
suppressor in hepatocellular carcinoma
134
. 
 
Figure 3.8: Filtering criteria for predicted miR-424 direct target identification. 
 
Table 3.6: Predicted direct targets of miR-424 identified through a multiple step filtering criteria. 
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3.2.5 MiR-424 modulates migration in cancer cell lines 
Following up on the pathway enrichment data implicating miR-424 regulates 
migration related pathways, we measured migration in vitro via scratch assays in lung 
adenocarcinoma cell lines developed from both smokers and never smokers. After 
knocking down miR-424, lung adenocarcinoma cell lines derived from ever smokers 
(Figure 3.9A) and never smokers (Figure 3.9B) were screened for a migration phenotype. 
The never smoker lung adenocarcinoma cell line H2085 was identified as having the 
strongest migration phenotype. In the H2085 cell line, efficient miR-424 knockdown 
results in a reduction of overall cell migration (Figure 3.10A, Figure 3.11A). This result 
is reproducible, with the averages of three separate experiments showing a reduction in 
overall cell migration by 10-20% (Figure 3.11B). Interestingly, overexpression of miR-
424 in a cell line with limited migration capacity, SK-LU-1, results in an increase of 
migration (Figure 3.10B, Figure 3.11C) that is consistent (Figure 3.11D).  
To ensure what we see by scratch assay is migration and not a result of 
proliferation, the scratch assays were stained for F-Actin at the time of scratch induction 
and at 24 hours after scratch induction. We see a decrease in the number of H2085 cells 
with a strong leading edge in cells transfected with anti-miR-424 (Figure 3.12A) and an 
increase in the number of SK-LU-1 cells with a strong leading edge with transfection of 
miR-424 mimic (Figure 3.12B). The lack of a proliferation phenotype affecting the 
scratch assay results is additionally supported by no change in cell cycle with miR-424 
knockdown (Figure 3.13A, Figure 3.13B) and no change in the number of cells staining 
for H3Sp10, a marker of mitosis (Figure 3.14A). Cells staining positive for H3Sp10 are 
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decreased, though not significantly, with a reduced serum environment (Figure 3.14B) 
but remain unchanged between cells transfected with control or anti-miR-424 in a serum 
rich media (Figure 3.14C). Growth in a low serum environment, transfected with control 
or anti-miR-424, and scratched also results in no change in H3Sp10 staining (Figure 
3.14D). 
 
Figure 3.9: Initial screening of lung adenocarcinoma cell lines identifies H2085 as having the strongest migration 
phenotype. Lung adenocarcinoma cell lines derived from (A) ever and (B) never smokers were transfected with anti-
miR-424 or control and measured for their capacity to close the induced scratch over 48 hours. Data shown is the 
difference in the % closure of the control – anti-miR-424 samples, therefore a higher % closure indicates a reduction in 
migration with the knockdown. 
 
Figure 3.10: Transfection of miR-424 mimic or anti-miR-424 dramatically changes miR-424 expression levels. 
qRT-PCR was used to measure (A) miR-424-5p knockdown efficiency in H2085 lung adenocarcinoma cells 
(p<0.00001) and (B) miR-424 overexpression efficiency in SK-LU-1 lung adenocarcinoma cells (p<0.05). 
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Figure 3.11: Perturbations of miR-424-5p in lung adenocarcinoma cell lines result in changes in migration. Cells 
are transfected with a control, anti-miR-424-5p, or miR-424 mimic. Photos are taken every 12 hours, shown are 
quantified results of the photos. Percent closure is calculated with TScratch. (A) Representative images of H2085 never 
smoker lung adenocarcinoma cell line shows a decrease in cell migration with miR-424 knockdown while (B) 
quantification of images over time show the change to be significant (p-value <0.05, n=3 experiments). (C) 
Representative images of SK-LU-1 smoker lung adenocarcinoma cell line shows an increase in cell migration with 
miR-424 overexpression and (D) quantification of the images show a strong increase in migration over time (p<0.005, 
n=3 experiments).  
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Figure 3.12: Perturbations of miR-424-5p in lung adenocarcinoma cell lines result affect the ability of the cells to 
form a leading edge for migration. (A) Staining with F-Actin shows a decrease in the number of cells with strong 
leading edge staining with anti-miR-424 but with (B) overexpression of miR-424 there is an increase in cells staining 
for a leading edge. Arrows point to cells with accumulated F-Actin on one side of the cell. 
 
Figure 3.13: Knockdown of miR-424 does not affect cell cycle in the H2085 cell line. (A) Cell cycle was measured 
using PI staining and FACS. (B) Quantification of the cell cycle phases by FlowJo shows no change between control 
and anti-miR-424 transfected cells.  
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Figure 3.14: Knockdown of miR-424 does not affect mitosis in the H2085 cell line. (A) Staining of cells with F-
Actin and H3Sp10, a marker of mitosis, show no change in the number of cells expressing the mitosis marker with 
around 1% of all cells expressing the marker. (B) Growing H2085 cells in 10% FBS (n=3) results in a slightly higher, 
but not significant, number of cells undergoing mitosis compared to H2085 cells grown in 1% FBS (n=3) as measured 
by staining for DAPI and H3Sp10. (C) H2085 cells grown in 10% FBS and transfected with control (n=3) or anti-miR-
424 (n=3) show no difference in the number of cells in mitosis and (D) cells grown in 1% FBS, transfected with either 
control (n=3) or anti-miR-424 (n=3), and had a scratch to the cell growth surface show no difference in the number of 
cells in mitosis. 
3.3 Materials and Methods 
Tumor and Adjacent Normal Adenocarcinoma Samples 
We received frozen lung adenocarcinoma tumor and adjacent normal tissues, 6 
never smoker patients and 13 ever smoker patients, from the tumor biorepository at the 
Mayo Clinic. These samples were obtained from the resected lobes of never smokers and 
ever smokers with lung adenocarcinoma, where tumor cell purity was ≥70%. Normal 
lung tissue was obtained from an area most distant from the tumor. Additional samples 
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were obtained from early stage (I-IIIA) resected lung adenocarcinoma collected and 
processed between 2011 and 2013 at the University of Texas MD Anderson Cancer 
Center. All 33 cases (14 never smoker patients and 19 ever smoker patients) from the MD 
Anderson Cancer Center included samples of lung adenocarcinoma and uninvolved 
normal lung parenchyma. IRB approval was obtained at all sites through an institutional 
ethics board and all study participants signed an informed consent form. 
Small Airway Brushings 
From the MD Anderson patients (14 never smoker patients and 19 ever smoker 
patients), adjacent (to tumor) histologically normal airway epithelial cells were obtained 
by brushing bronchiolar structures using sterile Cytosoft cytology brushes (Medical 
Packaging Corporation, Camarillo, CA) as previously described. Airway brushings were 
placed in Qiazol lysis buffer (Qiagen, Valencia, CA) in dry ice and immediately stored in 
-80°C. To confirm the content of airway epithelial cells, pan-cytokeratin 
immunohistochemical analysis (IHC) and analysis of neoplastic or pre-neoplastic cells 
were performed as previously described. 
qRT-PCR 
To measure the expression of miR-424-5p, 10 ng of total RNA was used in a 
Taqman MiRNA Assay (Life Technologies, Catalog #4427975, ID #000604, Carlsbad, 
CA) as per manufacturer’s protocol and the results were normalized to RNU44 
expression (Life Technologies, Catalog #4427975, ID #001094, Carlsbad, CA). To 
measure the expression of FOXP2, 500 ng of total RNA was reverse transcribed using 
RT2 First Strand Kits (Qiagen, Catalog #330401, Valencia, CA) according to the 
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manufacturer’s protocol. cDNA product was added to SYBR Green qPCR Mastermix 
(Qiagen, Catalog #330523, Valencia, CA) and FOXP2 primer (Qiagen, Catalog 
#PPH01974B, Valencia, CA). Data was normalized to the expression of UBC (Qiagen, 
Catalog #PPH00223F, Valencia, CA) and analyzed using the comparative CT method. 
Relative expression was compared using a student’s t-test. For both comparing qRT-PCR 
fold change of tumor vs adjacent normal for FOXP2 and miR-424-5p between ever and 
never smokers as well as for comparing fold change between EGFR status types, we 
utilized a Wilcoxon test. 
Cells and Cell Culture 
Never smoker lung adenocarcinoma cell line H2085 (obtained from ATCC, 
verified by ATCC, Manassas, VA) were grown in DMEM:F12 media supplemented with 
0.02 mg/ml insulin, 0.01 mg/ml transferrin, 25 nM sodium selenite, 50 nM 
hydrocortisone, 1 ng/ml epidermal growth factor, 0.01 mM ethanolamine, 0.01 mM 
phosphorylethanolamine, 100 pM triiodothyronine, 0.5% BSA, 10 mM HEPES, 0.5 mM 
sodium pyruvate, 2 mM L-glutamine and 10% FBS. Cells were subcultured as described 
by ATCC. The lung adenocarcinoma cell line SK-LU-1 (obtained from ATCC, verified 
by ATCC, Manassas, VA) was grown in EMEM supplemented with 10% FBS and 
subcultured as described by ATCC.  
Migration Assay 
H2085 was transiently transfected with hsa-miR-424-5p miRCURY LNA miRNA 
inhibitor or miRCURY LNA miRNA inhibitor control (Exiqon, Catalog #4104094-001, 
199006-001, Woburn, MA). SK-LU-1 was transiently transfected with hsa-miR-424-5p 
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mirVana miRNA mimic (Life Technologies, Catalog #4464066, ID #MC10306, 
Carlsbad, CA) or Negative Control #1 mirVana miRNA mimic (Life Technologies, 
Catalog #4464058, Carlsbad, CA). Cells were grown to full confluence and then serum-
starved in RPMI-1640 supplemented with 1% FBS for 24 hours. The plate surface was 
then scratched with a 200 µl tip and cells were kept in a serum-starved environment for 
the duration of the assay. Photographs of the scratch were taken every 12 hours at 50x 
magnification using the Zeiss inverted microscope, Axio Vert.A1 and the microscopy 
camera Axiocam 105 color. Photographs were taken using AxioVision SE64 Rel. 4.9.1 
SP1 software. Tiff images were analyzed using Matlab Compiler Runtime v7.8 with 
TScratch application v1.0.  
Cell Cycle Assay 
H2085 cells were grown and transiently transfected as previously described. Cells 
were collected 96 hours after transfection and fixed in 66% ethanol on ice. At the time of 
analysis cells were stained with 1X PI and RNase staining solution and incubated in the 
dark for 30 minutes. Cells were then examined with a FACS flow cytometer, 
FACSCalibur (BD Biosciences, San Jose, CA) and DNA histograms were analyzed with 
FlowJo v10.0.8. Each experimental condition was repeated in triplicate. 
Cell Staining 
Cells were fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton 
X. Cells stained for anti-histone H3 (phospho S10) (abcam, ab14955, Cambridge, MA) 
were blocked with 1% BSA and incubated overnight with the primary antibody. Cells 
were incubated with Alexa Fluor 546 goat anti mouse for two hours at room temperature 
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(Life Technologies, A11003, Carlsbad, CA). Alexa Fluor 488 Phalloidin (Life 
Technologies, A12379, Carlsbad, CA) was used to stain for F-Actin and ProLong Gold 
Antifade Mountant with DAPI (Life Technologies, P-36931, Carlsbad, CA) was used to 
mount and stain the cells for DAPI. Fluorescence was imaged at 40x using a Zeiss 
AxioSkop 40 microscope and a Zeiss AxioCam MRm black and white camera. Images 
were collected using the Axio Vision software (Release 4.6.3 SP1, 11-2007) and 
analyzed using ImageJ 1.43u software. 
Microarrays 
Total RNA from a knockdown study in H2085 cells (3 control, 3 knockdown) was 
isolated using the miRNeasy kit (Qiagen, 217004, Valencia, CA) and profiled by 
microarray (using the Affymetrix GeneChip Human Transcriptome Array HTA 2.0 
platform). CEL files were normalized to produce gene-level expression values using the 
implementation of the Robust Multi-array Average (RMA) in the affy package (version 
1.36.1) included in the Bioconductor software suite, and an Entrez Gene-specific probeset 
mapping (v16.0.0) from the Molecular and Behavioral Neuroscience Institute 
(Brainarray) at the University of Michigan. RMA was performed using the R 
environment for statistical computing (v2.15.1). Array quality was assessed by 
computing Relative Log Expression (RLE) and Normalized Unscaled Standard Error 
(NUSE) metrics using R and the affyPLM Bioconductor package (v1.34.0). RLE, NUSE, 
and PCA were used for outlier detection. Gene expression differences between 
knockdown and control were assessed using a t-test. Gene Set Enrichment Analysis 
(GSEA) was used to test for enrichment of a ranked gene list ranked based on the t-
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statistic of control versus experimental condition against selected gene sets from 
MSigDB.  
 
3.4 Discussion 
Building upon previous work showing transcriptomic differences between ever 
and never-smoker lung adenocarcinoma, we have identified one key driver microRNA, 
miR-424, which impacts cancer cell migration in vitro.  
MicroRNAs play a key role in regulating pathways and promoting oncogenic 
activity 
135,136
; they also serve as attractive molecular targets for cancer therapies. For this 
reason, by finding differentially expressed microRNAs involved in cancer, we are 
identifying microRNAs that can be further pursued as potential therapeutic targets. 
Analyzing the previously produced never smoker adenocarcinoma regulatory network, 
we were able to gain new insights into the role that microRNAs may play at the 
regulatory level to promote carcinogenesis in never smokers. It is through this analysis 
that miR-424 warranted our attention as a key hub in the network, exercising potential 
regulatory interactions with a large number of mRNA targets that participate in many 
pathways, particularly those deregulated in cancer, such as migration. Furthermore, miR-
424 itself has been reported to play an oncogenic role in colonic and pancreatic 
adenocarcinoma 
98,99
. Importantly, the unique differential expression of miR-424 in never 
smoker tumor versus adjacent normal was validated experimentally using qRT-PCR. The 
changes in miR-424 expression are independent of sample EGFR mutational status, 
implying that miR-424 works in different pathways then EGFR and its mechanism of 
  62 
action in cancer may expand our understanding of targetable pathways for therapeutic 
intervention. 
Building on the success of identifying a potential regulatory microRNA, we 
knocked down miR-424 in a never smoker lung adenocarcinoma cell line and detected 
perturbations in multiple migration pathways using gene expression arrays. To validate 
these findings, we proved the critical importance of miR-424 as a driver of a key cancer 
hallmark by demonstrating that knockdown of miR-424 in a never smoker cancer cell 
line (H2085) robustly and reproducibly reduces cancer cell migration. Additionally, in an 
adenocarcinoma cell line with little endogenous migratory potential (SK-LU-1) we 
overexpressed miR-424 and found the microRNA is capable of promoting cell migration. 
The miR-424 ability to modulate migration in vitro was supported by several lines of 
evidence, F-Actin staining demonstrated that the organized leading edge of H2085 cells 
upon the introduction of a scratch is lost with miR-424 knockdown. Conversely, SK-LU-
1 cells don’t present with leading edges until they are transfected with miR-424 mimic. 
Collectively, these experiments argue a role for miR-424 in cellular migration in lung 
adenocarcinoma. It must be noted, however, that many of the lung adenocarcinoma cell 
lines tested for a migration phenotype were not affected by knockdown of miR-424. 
Expression of miR-424 may have been low in some of these cell lines to begin with, 
preventing knockdown of miR-424 from having a strong reaction, or they may not be 
dependent on miR-424 for migration. SK-LU-1 is an example where the knockdown of 
miR-424 did not alter migration but overexpression did. Additional cell lines need to be 
tested for both miR-424 knockdown and miR-424 overexpression in regards to migration 
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to better understand the specific adenocarcinoma tumors that can be manipulated with 
miR-424 perturbations. Beyond the scope of this current work, it would be compelling to 
test if miR-424 plays a role in hallmarks of cancer other than migration, using both 
additional cell line assays and mouse models, as well as identify the specific pathways 
modulated with miR-424 perturbations that are responsible for the migration phenotype 
so that we can identify a targetable pathway in lung adenocarcinoma. 
Others have described local transcriptomic changes in tissue and the epithelium of 
small airways located proximal to the tumor in smokers 
137
 as well as in the epithelium of 
large airways of smokers 
138
. These seminal observations lead to the development of a 
minimally invasive bronchoscopy based diagnostic test for lung cancer in current or 
former smokers
139
. Very little is known about the field effect in never smokers with lung 
cancer. One study found EGFR mutations in the histologically normal bronchial and 
bronchiolar epithelia of patients with lung adenocarcinoma bearing EGFR mutations
140
. 
This study includes never smoker patients as well as former smokers, with no never 
smoker specific results highlighted. More recently, an article of the adjacent airway field 
of cancerization in NSCLC noted that, while they did not explore the field of never 
smoker lung adenocarcinoma, this area is relatively in need of future research
137
. In our 
study we present preliminary observational data that suggests that the high miR-424 
expression in never smoker tumors extends into the small airways of an independent 
cohort of never smokers with lung adenocarcinoma, raising the possibility of a 
transcriptomic field effect specific to never smokers. If miR-424 is indeed expressed 
more highly in the airways of never smokers with lung cancer as compared to their lung 
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cancer free counterparts it suggests the possibility of being able to develop a minimally 
invasive diagnostic test for lung cancer in never smokers. Our observation of a higher 
expression of miR-424 in the never smoker adjacent to tumor small airway has important 
implications for developing diagnostic tests for this cohort, but needs to be confirmed by 
profiling miR-424 in the small airways of never smokers without lung cancer as well as 
moving from the small airway, close to the tumor, to the large airways.  
3.5 Conclusions 
In conclusion, our results suggest that oncomiR miR-424 may be a therapeutic 
target in never smoker lung adenocarcinoma. Migration, a hallmark of cancer, is affected 
by miR-424 perturbations. By further exploring the mechanism by which miR-424 affects 
migration, we can potentially identify therapeutics to counteract the role of miR-424 in 
this disease. Although our results need to be confirmed with controls, the observation of 
miR-424 expression in the small airways near never smoker lung adenocarcinoma tumors 
combined by the already proven feasibility of transcriptome based biomarker 
development suggests yet another rapid path to clinical impact for our results. Validation 
of these profiles, including the activation of miR-424 as a potential oncomiR in the tumor 
versus adjacent normal of adenocarcinoma patients with no history of smoking, 
represents critical findings that may ultimately contribute to the clinical development of 
new therapies and diagnostics for lung adenocarcinoma in never smokers. 
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CHAPTER FOUR 
MicroRNA 34c 5’ IsomiR Regulates Ras Signaling Genes in Interstitial Lung 
Disease 
4.1 Introduction 
 Patients with interstitial lung diseases are characterized as having thickening of 
the supporting tissues between the alveoli of the lung
141
. Thickening can be due to a 
number of factors such as autoimmune diseases, exposure to toxins such as tobacco 
smoke, genetic diseases, or an unknown cause (idiopathic)
46,142
. A definitive diagnosis of 
a patient’s ILD is critical to identify a treatment, since they vary from antimicrobial 
agents, chemotherapy, avoidance behavior, to only palliative care
44,141
. The most 
common form of ILD is IPF, which has a median survival of three years from time of 
diagnosis and has no effective therapy available
48,143–145
. 
 Currently, ILD is described at the tissue level with processes such as apoptosis, 
fibrosis, aberrant wound repair, and scaring
146,147
. At the molecular level ILD is 
associated with dysregulation of TGF-ß and Wnt signaling pathways, extracellular matrix 
remodeling, and epithelial to mesenchymal cell transition
148–150
. Linkage studies have 
indicated dysregulation of MUC5B is associated with IPF
151
. 
 Very little is known about the role of microRNAs in ILD, with most of the focus 
on microRNAs that are associated with TGF-ß
148–150
. Because microRNAs perform 
critical functions as gene regulators in healthy biology as well as in many disease 
processes, it is important to characterize the microRNA role of ILD in relation to the 
disease onset and progression.  
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As part of the LGRC, our group previously sequenced the small RNA in lung 
tissue samples from patients with COPD (n = 150) or ILD (n = 149) and from normal 
lung (n=65) (Table 4.1).   
 
Table 4.1: Demographics of LGRC cohort sequenced with microRNA sequencing. The symbol * denotes 
significant difference (p<0.05) between the control and ILD cohorts. † denotes significant difference (p<0.05) between 
the control and COPD cohorts. ‡ denotes significant difference (p<0.05) between the ILD and COPD cohorts. Numbers 
in brackets denote samples with missing information in that field. 
Our group found that the expression of 255 microRNAs were significantly 
associated with the presence of disease (FDR < 0.05; absolute fold change > 1.25; Figure 
4.1A) while controlling for smoking status, age, total number of reads aligned to 
microRNA loci within a sample, and library preparation protocol. To characterize the 
heterogeneity observed within these disease-associated microRNAs, our group used 
consensus clustering to uncover five distinct subgroups of samples (s1-s5). Cluster s1 
contained the majority of control samples (33 out of 62; Figure 4.1B). Cluster s3 
contained the largest proportion of COPD patients while clusters s4 and s5 contained the 
largest proportions of ILD patients. Several clinical measures of disease severity were 
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associated with sample cluster status with each disease including DLCO in ILD and 
DLCO, FEV1 percent predicted, FEV1/FVC, percent emphysema, and BODE in COPD 
(p < 0.05; Figure 4.1C). 
Looking closely at the microRNA clusters identified by consensus clustering, m1-
m4 (Figure 4.1A), microRNA cluster m1 contained upregulated microRNAs in IPF 
clusters s4 and s5. The microRNAs in m1 are enriched for microRNAs located in the 
cluster on 14q32 as well as other microRNAs previously implicated in IPF such as miR-
21 and miR-154
73,152
. The microRNAs in cluster m2 are primarily responsible for the 
separation observed in ILD-associated clusters s4 and s5. Many of the m2 microRNAs 
are specifically expressed in airway epithelium and involved in airway differentiation 
including miR-449a/b/c, miR-34b/c, miR-4423, and miR-205
94
. MicroRNAs in m3 are 
primarily up-regulated in the COPD-enriched cluster s3 and included miR-15/16, miR-
144/451, as well as some microRNAs in the miR-17-92 cluster. Finally, microRNAs in 
cluster m4 included miR-30a/c/d and miR-218. 
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Figure 4.1: MicroRNA sequencing analysis of COPD and ILD tissue shows distinct clusters of microRNAs 
associated with the different diseases compared to control. (A) A total of 255 microRNA were identified as 
significantly associated with the presence of disease and using consensus clustering five disease subgroups, denoted in 
the first color bar with s1-s5, and four microRNA clusters, denoted on the left side of the heat map with m1-m4, were 
discovered. The second color bar shows the patient population, with black bars for control, yellow bars for COPD, and 
purple bars for ILD patients. (B) The five patient subgroups vary in their distribution of number of patients with each 
disease or control phenotype. (C) Many clinical measurements are associated with the subgrouping, including DLCO in 
ILD as well as DLCO, FEV1 percent predicted, FEV1/FVC, percent emphysema, and BODE in COPD (p<0.05). 
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 IsomiRs were recently identified and described as variants of what is known as 
the canonical microRNA sequence. These variants highlight that what is commonly 
known as the canonical form of a microRNA, identified by being the most highly 
expressed form of the microRNA via sequencing, is sometimes not the highest expressed 
form of the microRNA in all tissue and disease types
153,154
. Most isomiRs are variants on 
the 3’ end of the microRNA. A variant on the 5’ end of a microRNA, shifts the seed 
sequence, potentially affecting the targets of the microRNA
154,155
.   
To evaluate the potential role of microRNA isoforms with alternative seed 
sequences, reads were grouped according to their aligned start position within the 
microRNA precursor region and those with the different start positions were counted as 
separate transcripts. Our group focused on microRNAs in cluster m2 due to their ability 
to distinguish sample clusters s4 and s5 as well as their known roles in airway 
differentiation. The miR-449/34 family had some of the highest expressed non-canonical 
isomiRs in this cluster. miR-34c was upregulated in ILD patients and had a highly 
expressed 5’ isomiR (Figure 4.2). 
 
Figure 4.2: The top miR-34c variants by read count with RNA sequencing. The seed sequence (red) does not 
change with 3’ isomiRs but is shifted with the 5’ isomiR. 
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 Using TargetScan, predicted targets of miR-34c and the miR-34c 5’ isomiR were 
identified. Our group also performed all pairwise Spearman correlations between the 
expression of every gene and every microRNA. The distribution of genes predicted to 
have target sites for miR-34c canonical seed, the miR-34c 5’ isomiR seed, or both are 
enriched for genes that are anticorrelated to the microRNAs, compared to a control 
distribution of genes that are not predicted to be targets (p<0.01; Wilcoxon rank-sum test; 
Figure 4.3A). In order to further classify the biological processes targeted by miR-34c 
and the miR-34c 5’ isomiR, their individual as well as combined predicted targets were 
examined for pathway enrichment. Ras protein signaling was one of the top pathways 
enriched among genes that were significantly anti-correlated to miR-34c-5p locus 
expression (FDR<0.25) and that had a predicted binding site for the isomiR only 
(p<0.0005; Figure 4.3B). In addition, Ras protein signaling was also modestly enriched 
among anti-correlated genes that were predicted to be targets of both miR-34c and 
isomiR (p<0.05; Figure 4.5B). However this pathway was not enriched in anti-correlated 
miR-34c canonical-only targets. 
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Figure 4.3: Predicted targets of miR-34c and miR-34c 5’ isomiR include individual and co-targets that regulate 
Ras protein signaling. (A) The distribution of Spearman correlation coefficients between miR-34c-5p expression and 
gene expression is plotted for four different sets of genes: predicted targets of the 5’ miR-34c isomiR (blue), the 
canonical miR-34c (red), both (yellow), and neither (black). (B) Significantly anti-correlated (FDR<0.25) predicted 
targets of the 5’ miR-34c isomiR are enriched for Ras protein signaling genes (p<0.0005). 
Based on the data generated in these previous studies, we aim to characterize 
miR-34c, identified by RNA sequencing to be upregulated in ILD tissue compared to 
healthy tissue. miR-34c is not only dysregulated in ILD, but by sequencing we see that 
there is a 5’ isomiR of miR-34c that expands the potential targeting breadth for miR-34c. 
By modulating the expression of miR-34c and its 5’ isomiR, we seek to identify common 
and independent mRNA targets for these two variants. 
 
4.2 Results 
4.2.1 Validation of miR-34 expression in clinical samples 
 The behavior of miR-34c as well as the behavior of the other two miR-34 family 
members (miR-34a and miR-34b) was validated by qRT-PCR in a subset of patient 
samples (10 control, 10 ILD; Table 4.2). The differential expression of miR-34c between 
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control and ILD patient samples was confirmed by qRT-PCR (Figure 4.4A) but there was 
no significant difference in the expression of the other family members, miR-34a (Figure 
4.4B) and miR-34b (Figure 4.4C).  
 
Table 4.2: Demographics of LGRC samples used in qRT-PCR studies. 
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Figure 4.4: Upregulation of miR-34c in IPF tissue validates by qRT-PCR but miR-34a and miR-34b are not 
differentially expressed. (A) IPF (n=10) tissues have a significantly higher expression of miR-34c than control (n=10) 
tissues (p<0.05). The expression of (B) miR-34a is unchanging between IPF (n=10) and control (n=10) tissue while (C) 
miR-34b appears to have a small, but not significant, increase in expression in IPF tissue compared to control. 
4.2.2 Validation of miR-34c and miR-34c 5’ isomiR predicted targets in clinical samples 
 In order to validate the Ras protein signaling pathway genes identified as being 
predicted targets of miR-34c and/or the miR-34c 5’ isomiR, the expression of some of 
these genes was measured in clinical samples via a secondary platform, qRT-PCR. 
NOTCH1, a gene that has previously been described as a direct target of miR-34c and is a 
predicted target of the miR-34c 5’ isomiR is not a member of the RAS protein signaling 
pathway but serves as a positive control. NOTCH1 (p<0.0005; Figure 4.5J), as well as 
GRB2 (p<0.00005; Figure 4.5B), CRK (p<0.005; Figure 4.5C), CRKL (p<0.0005; Figure 
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4.5H), RHOC (p<0.005; Figure 4.5F), RALA (p<0.05; Figure 4.5A) and GRAP 
(p<0.0005; Figure 4.5D) all validate with significant downregulation of their expression 
in ILD samples compared to the control samples. Genes RHOA (Figure 4.5E), ARAP2 
(Figure 4.5G), and EGF (Figure 4.5I) do not validate as significantly differentially 
expressed. 
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Figure 4.5: Predicted targets of miR-34c variants validate as being dowregulated in ILD clinical tissue. Of the ten 
genes measured in clinical samples, nine of which are members of the Ras protein signaling pathway, seven validated 
as being downregulated in ILD compared to control tissue. These seven genes are: (A) RALA (p<0.05), (B) GRB2 
(p<0.00005), (C) CRK (p<0.005), (D) GRAP (p<0.0005), (F) RHOC (p<0.005), (H) CRKL (p<0.0005), and (J) 
NOTCH1 (p<0.0005). 
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4.2.3 Lung fibroblast cell line IMR90 allows for miR-34c regulation of NOTCH1  
 Lung fibroblast (IMR90) and basal airway (HBEpC) cells were transfected with 
mimics of miR-34c, the miR-34c 5’ isomiR, or both in order to identify targets of these 
microRNA. Leveraging the knowledge that NOTCH1 has been well described as a direct 
target of miR-34c
156,157
 and in our data is a predicted target of the miR-34c 5’ isomiR, it 
was the first gene profiled by qRT-PCR to identify which cell line would be best for 
subsequent experiments. In fibroblast cells transfection with all variations of the mimics 
downregulated the overall gene expression of NOTCH1 significantly (p<0.005, p<0.005, 
p<0.005; Figure 4.6A). In basal airway cells, none of the conditions resulted in a change 
in NOTCH1 expression (Figure 4.6B). Based on the results of the positive control, all 
additional experiments were done in IMR90 cells.  
 
Figure 4.6: IMR90 fibroblast cells are sensitive to miR-34c transfections as evidenced by positive control 
NOTCH1 gene expression. Cells transfected with miR-34c mimic, miR-34c 5’ isomiR mimic, or both were measured 
for NOTCH1 gene expression. (A) IMR90 fibroblast cells show significant repression of NOTCH1 with all 
experimental transfections (p<0.005, p<0.005, p<0.005). (B) HBEpCs show no significant change in NOTCH1 
expression compared to control. 
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4.2.4 MiR-34c 5’ isomiR has targets independent of the canonical miR-34c 
 In IMR90 cells transfected with mimics of miR-34c, the miR-34c 5’ isomiR, or 
both miR-34c and the miR-34c 5’ isomiR, there are members of the Ras protein signaling 
pathway that are affected only by transfection with the miR-34c 5’ isomiR mimic. Of the 
genes that validate as being downregulated with miR-34c 5’ isomiR mimic transfection, 
GRB2 has the greatest gene expression downregulation (p<0.005; Figure 4.7A) and 
CRKL has a smaller change (p<0.05; Figure 4.7B). To validate that we are in fact seeing 
a change in gene expression with miR-34c 5’ isomiR overexpression and not an artifact, 
NOTCH4 was measured in the same samples. NOTCH4 is a known target of miR-34c
158
 
and is not predicted to be targeted by the miR-34c 5’ isomiR. Expression of NOTCH4 is 
significantly decreased with miR-34c overexpression (p<0.005; Figure 4.7C).  
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Figure 4.7: The miR-34c 5’ isomiR and the canonical miR-34c have independent targets. (A) GRB2 is 
significantly downregulated with the miR-34c 5’ isomiR mimic transfection (p<0.005, p<0.005) but not the miR-34c 
canonical transfection. (B) CRKL is also significantly downregulated with the miR-34c 5’ isomiR mimic transfection 
(p<0.05, p<0.05) but not the miR-34c canonical transfection. (C) NOTCH4 expression is decreased with miR-34c 
mimic transfection (p<0.005). 
4.2.5 Expression of miR-34 family members are affected by overexpression of miR-34c 
To determine if other members of the miR-34 family were affected by flooding 
the cells with miR-34c and 5’ miR-34c isomiR mimics, miR-34a and miR-34b expression 
were measured by qRT-PCR. The expression of miR-34b measures as significantly 
increased with miR-34c mimic transfection, this is most likely an artifact of the primer 
measuring miR-34c expression as well as miR-34b (p<0.000005, p<0.0005; Figure 
4.8A). Interestingly, miR-34a expression is reduced with transfection of any of the 
mimics (p<0.0005, p<0.005, p<0.005; Figure 4.8B). 
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Figure 4.8: MiR-34 family members are affected by miR-34c and miR-34c 5’ isomiR overexpression. (A) The 
expression of miR-34b is increased with miR-34c overexpression (p<0.000005, p<0.0005). (B) miR-34a expression is 
downregulated with both miR-34c and the miR-34c 5’ isomiR transfections (p<0.0005, p<0.005, p<0.005). 
 
4.3 Materials and Methods 
Control and ILD Samples 
A subset of samples obtained from the NHLBI funded LTRC
159
 that we 
performed small RNA sequencing on were used to perform qRT-PCR validation. 
qRT-PCR 
To measure the expression of miR-34a-5p, miR-34b-5p and miR-34c-5p, 10 ng of 
total RNA was used in a Taqman MiRNA Assay (Life Technologies, Catalog #4427975, 
ID #000426, 000427, 000428, Carlsbad, CA) as per manufacturer’s protocol and the 
results were normalized to RNU44 expression (Life Technologies, Catalog #4427975, ID 
#001094, Carlsbad, CA). To measure the expression of RALA, GRB2, CRK, CRKL, 
GRAP, RHOA, RHOC, EGF, ARAP2, NOTCH4 and NOTCH1, 500 ng of total RNA was 
reverse transcribed using RT2 First Strand Kits (Qiagen, Catalog #330401, Valencia, CA) 
according to the manufacturer’s protocol. cDNA product was added to SYBR Green 
qPCR Mastermix (Qiagen, Catalog #330523, Valencia, CA) and the appropriate primer 
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(Qiagen, Catalog #PPH07458A, PPH00714C, PPH00731A, PPH01982A, PPH13173A, 
PPH00305G, PPH01089E, PPH00137B, PPH20012A, PPH06021F, PPH00526C, 
Valencia, CA). Data was normalized to the expression of UBC (Qiagen, Catalog 
#PPH00223F, Valencia, CA) and analyzed using the comparative CT method. 
Transfection 
 IMR90 cells and HBEpCs were transiently transfected with hsa-miR-34c-5p 
miRIDIAN miRNA mimic (Dharmacon, Catalog #C-300655-03-0020, Lafayette, CO), a 
custom miR-34c 5’ isomiR miRIDIAN miRNA mimic (Dharmacon, Lafayette, CO) or 
miRIDIAN miRNA mimic Negative Control #1 (Dharmacon, Catalog #C-001000-01, 
Lafayette, CO). IMR90 cell transfection was completed using Lipofectamine RNAiMAX 
transfection reagent (Life Technologies, Catalog #13778150, Carlsbad, CA) according to 
the manufacturer’s protocol. Transfection of HBEpCs was done using Cytofect Epithelial 
Cell Transfection Kit (Cell Applications, Catalog #TF102K, San Diego, CA). 
4.4 Discussion 
 The sequencing of tissue from control and ILD samples led to the discovery of 
miR-34c being upregulated in ILD. Expanding on these studies, we have shown that not 
only is miR-34c upregulated in ILD patient tissues compared to controls, but that the 
expression of miR-34c 5’ isomiR leads to regulation of members of the Ras signaling 
pathway. 
 Very little is known about the molecular underpinnings of ILD. In order to better 
understand and treat the diseases listed under the umbrella of ILD, the microRNAs 
dysregulated with the onset and progression of the disease as well as the networks of 
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mRNA affected by these microRNAs need to be investigated. By doing this, we can 
better diagnose and treat ILD. The work done in this study validates the expression of 
miR-34c seen in small RNA sequencing data and characterizes the targets of a miR-34c 
5’ isomiR detectable by RNA sequencing.  
We show that miR-34c is upregulated in ILD tissue compared to control tissue 
and that this dysregulation is specific to miR-34c and not other miR-34 family members 
miR-34a and miR-34b. These results indicate a specific role for miR-34c in ILD, 
especially since miR-34b and miR-34c share a promoter and are commonly transcribed 
together.  
Previously, through the use of target prediction software, we saw that miR-34c 
and the miR-34c 5’ isomiR predicted targets are enriched with members of the Ras 
signaling gene family. Furthering these studies, we measured the predicted targets of 
miR-34c and the miR-34c 5’ isomiR gene expression in ILD and control tissues with a 
secondary platform (qRT-PCR), and confirmed that a number of these genes are in fact 
downregulated in ILD tissue. The large family of Ras signaling genes are important 
mediators of many pathways such as EGFR, PI3K, and MAPK
160
. Interestingly, ILD has 
been shown to have an uncommon but strong adverse reaction to EGFR inhibitors used in 
the treatment of lung cancer
161,162
. Together, these results potentially indicate a role for 
EGFR in ILD progression. A better understanding of the Ras signaling genes that are 
dysregulated with ILD progression could uncover the mechanism by which these EGFR 
inhibitors are impacting ILD. 
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Turning to cell biology techniques, we overexpressed miR-34c and miR-34c 5’ 
isomiR in a fibroblast cell line and saw a significant decrease in NOTCH1, a positive 
control, with both miR-34c and miR-34c 5’ isomiR expression. We also observed a 
significant decrease in GRB2 expression with only the miR-34c 5’ isomiR 
overexpression, indicating a specific role for the isomiR in regulating GRB2. With GRB2 
being an important upstream regulator of the EGFR pathway
163–165
, the regulation of this 
gene by the miR-34c 5’ isomiR has the potential to have important therapeutic 
implications if the EGFR pathway is found to be a regulator of ILD. Currently, there is 
research showing the EGF 61A/G polymorphism is associated with sporadic ILD
102
 and 
increased expression of EGFR in three ILD diseases
166
, leading credence to the concept 
that the EGFR pathway may be dysregulated in ILD. 
Also of interest, miR-34a expression is significantly downregulated following 
overexpression of miR-34c or the miR-34c 5’ isomiR. MiR-34a is well known to be a 
regulator of the EGFR pathway
167,168
. While the downregulation of miR-34a with 
overexpression of miR-34c or its variant is an unexpected result, it’s possible that there is 
compensation in the cell between these two microRNAs to prevent overregulation of the 
EGFR pathway. Further studies are needed to test this hypothesis.  
There appear to be mRNA targets in common and specific to miR-34c and the 
miR-34c 5’ isomiR. This is not unlike the role different microRNA family members 
have, with the distinction being that instead of being produced from different areas of the 
chromosome, the same pre-miRNA can be cleaved to produce variants. Future studies are 
needed to better understand the mechanism by which isomiRs are produced during the 
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microRNA production process. Additional studies are also needed to better understand 
the role of the EGFR pathway in ILD progression and the phenotypes that are regulated 
by the miR-34c variants in these diseases. 
 
4.5 Conclusions 
 The data produced in these studies show an upregulation of miR-34c in ILD tissue 
compared to control. Furthermore, we have shown that miR-34c and the miR-34c 5’ 
isomiR have shared as well as individual targets for regulation and that Ras signaling 
genes are regulated by the 5’ miR-34c isomiR, genes that can in turn regulate the EGFR 
pathway. Further studies are needed to better understand the role of the EGFR pathway in 
ILD as well as the potential role of the miR-34c 5’ isomiR in regulating this pathway as a 
therapeutic or therapeutic target. 
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CHAPTER FIVE 
General Conclusions and Future Directions 
 
The research featured in this dissertation collectively identifies microRNAs that 
are dysregulated in lung diseases and describes their potential role in these diseases 
through the use of cellular and molecular biology techniques. All the microRNA 
identified in this document have the potential to be utilized as therapeutics or leveraged to 
identify therapeutic targets in lung cancer and ILD with further follow-up studies. 
Specifically, the results from this dissertation assert that: 
 The microRNA miR-4423 is expressed in the airway after the beginning of the 
differentiation of airway basal cells in a manner that correlates with ciliated 
cell markers and overexpression of this microRNA in the airway epithelium 
induces ciliogenesis. In addition, the expression of miR-4423 is lost during the 
progression of squamous cell carcinoma and can potentially be utilized as a 
cancer therapeutic in patients with this disease. These studies highlight the 
importance of understanding a microRNA’s role in normal regulation to 
recognize the consequence of its dysregulation. 
 miR-424 is a microRNA that is specifically upregulated in never smoker lung 
adenocarcinoma and potentially regulates a large number of cancer related 
pathways in lung adenocarcinoma. By modulating the expression of miR-424 
in lung adenocarcinoma cell lines, we show that miR-424 modulates a 
migration phenotype in this disease. The experiments in this study stress the 
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need to look into personalized therapies and put forth the idea of using miR-
424 as a therapeutic target in never smoker specific lung adenocarcinoma. 
 MicroRNAs have many variants associated with their expression and these 
variants have the potential to expand the network of genes that a microRNA 
can regulate. In ILD, miR-34c and isomiRs of miR-34c are upregulated, 
potentially regulating Ras signaling genes and pathways such as EGFR to 
progress the disease. Additional experiments show that a 5’ isomiR of miR-34c 
and the canonical form of miR-34c are functionally able to target independent 
and shared mRNA. The results of these studies bring to light the variation we 
see with each microRNA and caution that when we think of a microRNA as a 
therapeutic option, we take into account all the variants associated with that 
microRNA. 
The continued study of microRNAs in disease may facilitate a better 
understanding of a microRNAs regulatory role in the cell. Advancing our knowledge of 
microRNAs will allow for better understanding of their potential for therapeutic 
applications. The work outlined in this document highlight the variable roles microRNAs 
have in the cell, from driving differentiation and disease to regulating numerous 
pathways by the formation of isomiRs, the full potential of an individual microRNA is 
currently still an area of exploration. 
The results of these studies make a case for microRNAs playing key roles in 
disease biology and therefore highlight the limitless potential of using microRNAs for 
therapeutics. While future experiments are needed to fully understand the implications of 
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using the microRNAs outlined in this document for therapeutic purposes, the studies in 
this dissertation argue for improved overall understanding of the biology of microRNAs 
so that we can better employ microRNAs as therapeutics. There are many unanswered 
questions in regards to microRNAs that hinder our knowledge on how to best use them in 
translational science. It is only with further research into this field that we can better 
utilize the potential of microRNAs in regards to treating, and even preventing disease. 
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